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Abstract 
 
To protect against sexual transmission, successful future HIV vaccines will likely be given to 
adolescents as a booster subsequent to primary immunization during infancy. In sub-Saharan 
Africa (SSA), a large proportion of children are chronically infected with a variety of 
helminths.  These infections may suppress the ability of a host to elicit vaccine-induced Th1 
responses that are considered important for a successful HIV vaccine.  This study investigated 
the effect of chronic helminthic infection on the boosting capacity of a poxvirus-protein HIV 
vaccine regimen (SAAVI MVA-C and Env gp140 protein) in a mouse model.  
Groups of mice were prime-vaccinated with SAAVI MVA-C through an intramuscular 
injection, and Env gp140 protein formulated in Alum adjuvant which was administered via an 
intraperitoneal injection.  These vaccinations were given concurrently, two weeks prior to 
infection with Schistosoma mansoni (Sm) through a percutaneous route.  Control mice were 
either left uninfected (Naïve) or infected in the same manner (Sm) without vaccination. A 
booster vaccination was given eight weeks post helminth infection.  HIV-specific immune 
responses were analysed in the blood and spleens two weeks after booster vaccination.  
The magnitudes of cumulative IFN-γ ELISPOT responses to HIV Gag, RT and Env peptides 
were significantly (p<0.05) lower in the vaccinated and helminth-infected (Vaccine+Sm) mice 
(948 sfu/106) than vaccinated and uninfected (Vaccine) mice (1733 sfu/106), with IFN-γ 
responses to RT (CD8) being the most dominant for both mouse groups (Vaccine+Sm: 734 ± 
221 sfu/106, Vaccine: 521 ± 116 sfu/106).  No significant difference was observed in the 
magnitudes of cumulative IL-2 ELISPOT responses to the vaccine peptides between the 
Vaccine+Sm and Vaccine groups, however IL-2-producing T cell responses to Env (CD4) 
dominated in both mouse groups.  Vaccine+Sm and Sm groups had similar IFN-γ- and IL-2-
producing T cell responses to SEA.  Splenocytes from Vaccine+Sm mice secreted less Th1 
 xi 
 
(IFN-γ, IL-2, TNF-α) and Th2 (IL-4, IL-6, IL-10) cytokines than those from uninfected 
vaccinated mice in response to HIV vaccine peptides.  The total number of activated CD4+ T 
cells responding to vaccine peptides was greater for Vaccine+ Sm mice than Vaccine mice 
(p<0.05), however, no such statistical significance was observed in the differences seen 
between these vaccinated mouse groups for the number of activated CD8+ T cells.  The 
frequencies of central memory activated CD4+ T cells were seen to be greater in Vaccine group 
(Gag; 34.28 ± 8.35%, Pol; 33.53 ± 6.34%, Env (CD4); 33.92 ± 3.87%, Env (CD8); 38.76 ± 
10.52%) as opposed to the Vaccine+Sm group (Gag; 28.09 ± 3.95%, Pol; 26.45 ± 4.66%, Env 
(CD4); 28.79 ± 6.95%, Env (CD8); 28.65 ± 3.29%).  Furthermore, Vaccine+Sm mice had 
higher titres of HIV-1 gp140-specific IgG1 antibodies (p<0.0001) (a Th2 antibody marker) but 
significantly less gp140-specific IgG2a (p<0.0001) and IgG2b (p<0.001) (Th1 antibody 
markers) antibodies.  This trend was also observed with total non-Env-specific antibody titres.     
This study demonstrates that chronic helminthic infection is associated with an attenuated 
boosting capacity of a poxvirus-protein HIV vaccine in a mouse model, suppressing both T cell 
cytokine production and Th1-type antibody responses.  Since HIV vaccine-induced Th1 
responses are considered important for a successful HIV vaccine, these data suggest that 
chronic helminthiasis may impact negatively on future HIV vaccination outcomes in 
adolescents living in SSA where helminthic parasites are endemic. 
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1. Literature Review 
1.1  HIV Virology 
Human immunodeficiency virus (HIV) is a member of the Retroviridae family, in the 
Lentivirus genus, together with the simian, feline and bovine immunodeficiency viruses (Nye 
& Parkin, 2003).  These enveloped viruses all cause characteristically slow and steadily 
progressive infections and are transmitted by sexual contact, injection of infected blood or 
blood products, and from mother-to-child during delivery or breastfeeding (CDC, 2009).  The 
HIV genome consists of two identical copies of a single-stranded, positive sense RNA of 9.2 
kb in size (Feinberg & Greene, 1992).  As shown in Figure 1.1, it encodes for typical retrovirus 
proteins such as Gag, which is cleaved into matrix, capsid and nucleocapsid proteins, Pol, 
which is also cleaved further into protease, reverse transcriptase and integrase, and Env, a 
glycoprotein, again, cleaved into gp120 external subunit and a gp41 transmembrane subunit 
that, together, form trimeric prongs on the surface of the virion (Feinberg & Greene, 1992).  In 
addition to Gag, Pol and Env, the RNA of HIV also encodes for regulatory proteins Tat and 
Rev, as well as accessory proteins Nef, Vif, Vpr and Vpu (Girard et al., 2011).   
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Figure 1.1 - The genome structure of HIV with protein precursors and final products. The gag gene is 
translated into the structural Gag precursor (p53) that is cleaved into matrix (MA), capsid (CA), nucleocapsid 
(NC) and p6.  The pol gene is translated as a Pol precursor (p160) that is further cleaved into enzymes reverse 
transcriptase (RT), integrase (IN) and protease (PR). The env gene encodes for the structural precursor Env 
(gp160) which is cleaved into the extracellular (gp120) and intracellular (gp41) glycoproteins (adapted from Li & 
De Clercq, 2016).  
 
1.2 HIV Epidemiology 
1.2.1 Global epidemiology 
Since its discovery in the early 1980s, HIV has infected over 60 million people, with the 
resultant acquired immunodeficiency syndrome (AIDS) developing into one of the leading 
causes of death worldwide, with an estimated 2 million deaths per year (Barré-Sinoussi et al., 
1983; Girard et al., 2011; Koff et al., 2013).  It is estimated that 36.7 million people are 
currently living with HIV globally (UNAIDS, 2016a). 
There are two types that affect humans; HIV-1 and the less virulent HIV-2 (Barré-Sinoussi et 
al., 1983; Clavel et al., 1986).  It is hypothesised that HIV-1 in humans originated from cross-
species transmission from chimpanzees, and HIV-2 from sooty mangabeys (Hahn et al., 2000; 
Lemey et al., 2003; Sharp, Shaw & Hahn, 2005).  Groups of HIV-1 is further divided into 4 
Translation 
Protein cleavage 
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groups defined as M (major), O (outlier), N (non-M, non-O) and P (Charneau et al., 1994; 
Simon et al., 1998; Plantier et al., 2009).  Group M viruses are responsible for the majority of 
the world’s infections and, within this group, there are several subtypes or clades (named A to 
K) that exist and dominate different regions of the globe (McCutchan, 2000; Korber et al., 
2001).  Subtype B dominates in the Americas, Europe and Australia whereas subtype C is 
spread throughout southern Africa and India and subtype D strains are found in East and West 
Africa (McCutchan, 2006). 
 
 
1.2.2 HIV in sub-Saharan Africa and South Africa 
It is estimated that, of the 36.9 million people currently living with HIV globally, sub-Saharan 
Africa (SSA) accounts for estimated 25.8 million infected individuals as shown in Figure 1.2 
(UNAIDS, 2015).  With an estimated 1.4 million new HIV infections in sub-Saharan Africa in 
the last year, with 190 000 of those being new infections in children, while a decrease from 
previous years (1.5 million new HIV infections and 210 000 new infections among children in 
Figure 1.2 - Adults and children estimated to be living with HIV (Source: UNAIDS, 2014) 
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2013), this epidemic is far from abating and remains a large concern (UNAIDS, 2015).  Sub-
Saharan Africa is estimated to account for 75% of the world’s HIV-infected women and over 
80% of the world’s HIV-infected children and AIDS orphans.  (Nye & Parkin, 2003).  South 
Africa has the highest number of infected people, with an estimated 7 million people living 
with HIV by the end of 2015, which is an increase from 6.8 million in 2014 and 6.4 million in 
2011 (UNAIDS, 2016a).  Prevalence rates in South Africa in 2015 were 19.2%, only lower 
than Botswana (22.2%) (UNAIDS, 2016a).  However, it was reported that prevalence varies 
between the provinces, ranging from 27.9% in KwaZulu Natal to 7.8% in the Western Cape in 
15-49 year olds in 2012 (Shisana et al., 2014). 
1.2.3 HIV/AIDS as an economic burden in sub-Saharan Africa 
The impact of this epidemic in Africa is evident in the increased mortality rates and decreased 
life expectancy.  This has been demonstrated in rural parts of Kenya where 25% of adults were 
infected with HIV and the resulting life expectancy was 38 years (Buve, Bishikwabo-Nsarhaza 
& Mutangandura, 2002).  In South Africa, UNAIDS has stated that the annual number of 
AIDS-related deaths was about 180,000 in 2015 (UNAIDS, 2016a).  The U.S. Census Bureau 
has sited South Africa as the country with the lowest life expectancy at birth of 49.7 years in 
2015 and cited HIV/AIDS-related deaths as a factor (He, Goodkind & Kowal, 2016).  An 
indirect effect of high mortality rates would be an increase in orphans and thus increased family 
poverty and socioeconomic losses to the community (Buve, Bishikwabo-Nsarhaza & 
Mutangandura, 2002).  South Africa alone is reported to have 2.1 million orphans between the 
ages of 0 and 17 due to AIDS as of 2015 (UNAIDS, 2016a). 
A major strategy for managing HIV and the related mortality rates is the utilisation and 
distribution of highly active antiretroviral therapy (HAART).  These medicinal interventions 
in the form of antiretroviral treatments (ART) come in various drug compositions and 
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combinations.  These therapy regimens have been shown to significantly reduce the rates of 
morbidity and mortality associated with HIV/AIDS (UNAIDS, 2013a).  However, HAART is 
costly and necessitates life-long adherence as well as regular hospital and doctor check-ups.  
Thus, HIV positive individuals would consume a high amount of resources for the duration of 
their lifetimes to utilise these life-saving therapies.  An individual from a low-income 
household may have to depend on government or charitable assistance, although countries with 
the highest HIV positive populace are generally third world countries with a low GDP and 
resource constrained governments which may not be able to afford to provide for all the people 
who need these therapies (UNAIDS, 2016b).  About 46% of all adults living with HIV, and 
49% of all HIV positive children were able to get treatment in 2015.  Thus more than half of 
HIV positive individuals did not receive treatment (UNAIDS, 2016b). 
The UNAIDS (2016b) estimates that funding needed by low- and middle-income countries will 
need to increase from $19 billion in 2015 to $26.2 billion in 2020 in order to curb the epidemic 
effectively.  As sub-Saharan Africa is the region with the highest HIV burden, it accounts for 
the largest proportion of global HIV spending; 47% in 2012 (UNAIDS, 2013b).  More 
developed countries have increased their funding and support for HIV and AIDS prevention 
strategies and research in sub-Saharan Africa recently, with most donations going through the 
Global Fund.  By way of this fund, 2.3 million people in sub-Saharan received ART in 2010. 
Also, the Global Fund finances all of the ART programmes in numerous countries in sub-
Saharan Africa including Ethiopia, Ghana, Guinea, Malawi, Namibia and Tanzania (Global 
Fund, 2011).  As such, a total of 80% of finances for HIV programmes in sub-Saharan Africa 
was from donor funding (International AIDS Society, 2010).  However, South Africa, the 
country with the most people living with HIV, funds most of its own HIV response and 
programs and only relies on 20% of its HIV funding from international funding opportunities 
(South African National AIDS Council, 2015).  Based on South Africa’s National Strategic 
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Plan 2012-2016 targets, the discrepancy between funding requirements and available funding 
for HIV is expected to increase (South African National AIDS Council, 2015).  Also, in recent 
years, South Africa has been working to negotiate lower prices for ART, as it has been paying 
more than most other low and middle income countries regardless of having the world’s largest 
procurement programme (South African National AIDS Council, 2015).  Through a more 
competitive bidding process, South Africa managed to reduce the cost of buying ART to the 
lowest price anywhere in the world in 2013, a 53% reduction in spending on ART (UNAIDS, 
2013c). 
While funding is important for a country’s HIV treatment and prevention programmes to 
succeed, the health and education infrastructure to be developed sufficiently in order for 
implementation of any large-scale program to thrive.  Many countries in sub-Saharan Africa 
have come under increasing economic pressure as the epidemic has evolved, worsened further 
by the shortage of trained healthcare professionals in the region (World Health Organisation 
(WHO), 2007). 
1.3  Development of HIV-1 Vaccines 
1.3.1  The necessity for an HIV vaccine 
A number of countries in sub-Saharan Africa have conducted large-scale prevention 
programmes in an effort to contain and reduce their HIV epidemics.  One of the cost-effective 
strategies implemented to prevent the spread of HIV is the promotion of condom use.  While 
UNAIDS (2016) estimates that, since 1990 to present day, 45 million HIV infections around 
the world have been averted through condom use, in sub-Saharan Africa, the degree of condom 
use remains low (Maticka-Tyndale, 2012).  Another strategy has been to increase prevention 
of mother-to-child transmission (PMTCT) by ART (UNAIDS, 2014).   But there is evidence 
that progress is slowing in the scaling up of ART for pregnant women; 37,000 additional 
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pregnant women were reached by PMTCT programmes in 2013 compared with 97,000 in 
previous years (UNAIDS, 2014).  In many sub-Saharan countries, such as Chad, Lesotho, 
Uganda and Zimbabwe, there has been a decrease in number of pregnant women receiving 
ART.  Similarly for promotion of voluntary medical male circumcision, following years of 
rapid increase, within 8 of the 14 sub-Saharan countries surveyed, circumcisions performed 
declined in 2015; from 3.2 million in 2014 to2.6 million in 2015 (UNAIDS, 2016a).  Harm 
reduction and antiretroviral treatment (ART) have also had limited success (UNAIDS, 
2016a,b). 
As such, globally, the number of deaths associated with HIV infections have decreased in 
recent years due to the varying degrees of success of the numerous aforementioned prevention 
and treatment strategies, (UNAIDS, 2014).  However, the unrelenting spread of the viral 
infections continues to surmount these efforts, especially in SSA (Girard et al., 2011).  South 
Africa alone had 380 000 new infections in 2015 (UNAIDS, 2017).  In the past, vaccines have 
been our best weapon against the world’s deadliest infectious diseases, for example smallpox, 
polio, measles, and yellow fever (Siegrist, 2008a).  Therefore, candidate HIV vaccines have 
been designed with the aim of developing an effective, durable and affordable method for 
combating the HIV epidemic (Cohen & Dolin, 2013).   
1.3.2 Vaccine strategies 
Current strategies to develop novel vaccines can be divided into traditional and novel strategies.  
Traditional strategies include live attenuated viruses, whole killed viruses and protein subunits.  
Novel strategies include recombinant vaccines, DNA vaccines and novel methods of presenting 
vaccine antigens.  
Live attenuated virus vaccines have proved successful in the yellow fever, mumps and measles 
vaccines (Minor, 2015).  Non-human primate challenged with SIV represent an animal model 
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to test various vaccine strategies and to inform the design of HIV vaccine strategies (Koff et 
al., 2006; Silvestri et al., 2007; Morgan et al., 2008).  Attenuated SIV vaccines have shown 
some degree of success against SIV challenges in rhesus macaques (Daniel et al., 1992; Wyand 
et al., 1996; Siegrist, 2008b).  Nevertheless, it is generally accepted that an attentuated version 
of HIV will not get to human trials due to safety concerns (Baba et al., 1999).  Whole killed 
virus has shown some promise, and was demonstrated to be capable of protecting 8 out of 9 
rhesus macaques from SIV challenges in one study, but unable to produce high titres of broadly 
neutralising antibodies (Murphey-Corb et al., 1989).  Protein subunits have also been tested in 
various studies and showed no significant protection nor the ability of the vaccines to elicit 
observable protective humoral nor cellular immunity (Flynn et al., 2005; Pitisuttithum et al., 
2006). 
Live recombinant, or vectored, vaccines are designed to transport HIV antigens such as Gag, 
Pol, Env, or Nef within a live viral/bacterial vector.  These antigens are then expressed in the 
cytoplasm of infected cells in order to be presented on the MHC class I molecules to prime 
celullar T cell responses.   
1.3.3  Challenges in developing HIV Vaccines 
An ideal HIV vaccine is considered to be capable of both induction of potent T cell mediated 
immune responses as well as a durable humoral immune response through antibody production 
(Johnston & Fauci, 2007, 2011; Fauci et al., 2008; Ross et al., 2010; Chhatbar et al., 2011; 
Cohen & Dolin, 2013; Haynes & McElrath, 2013; McMichael & Koff, 2014).  Cohen and Dolin 
(2013) postulate that a successful HIV vaccine would stimulate protective immunity similar to 
that induced during a natural infection but acknowledge that naturally acquired immunity might 
not exist.  Therefore this would suggest that the mechanisms of an effective vaccine might need 
to induce an immune response completely different from that observed in natural infection 
(Johnston & Fauci, 2011).  
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Barouch (2008) holds that the goal of an HIV-1 vaccine would be to completely block and 
prevent infection or, alternatively, to reduce viral loads and slow clinical disease progression 
after infection has taken place.  However, the task has proven challenging for numerous 
reasons, possibly the greatest being the extensive sequence and clade diversity of HIV-1 
(Gaschen et al., 2002). Other challenges include the early establishment of a latent viral 
reservoirs, the lack of understanding and observance of immune correlates, the evasion of 
humoral and cellular immune responses by the virus, antibody responses being fairly type 
specific, the inability of current techniques to elicit broadly reactive neutralising antibodies, 
the safety concerns surrounding attenuated viruses in humans as well as the declining 
pharmaceutical interest (Barouch, 2008).  
Most successful viral vaccines that have been developed are against viruses that undergo some 
form of initial replication and distribution from the point of entry before the virus reaches its 
target organ (Johnston & Fauci, 2007).  During this dispersal period, the virus is exposed to 
eradication by the immune system and, when prior immunization or exposure to the virus has 
provided virus-specific immunologic memory, the increased speed and intensity of the immune 
response can prevent disease (Johnston & Fauci, 2007).  This is not unlike the initial stage of 
HIV infection.  The HIV viremia burst is detected around day 7 of infection and peaks around 
3 weeks after exposure.  Increased levels of HIV-specific CD8+ and CD4+ T cells stand as the 
first indications of HIV-specific immune responses (Johnston & Fauci, 2007).  A pool of 
latently infected, resting CD4+ T cells is established early in infection but the primary CD8+ 
T cell response seems to result in a decline of viral load, by a factor of 10 to 100, until a stable 
plateau or “set point” 2-6 months after infection (Koup et al., 1994).  Meanwhile, binding 
antibodies emerge 6-12 weeks after exposure but neutralizing antibodies only appear closer to 
the point of equilibrium (Johnston & Fauci, 2007).  The effectiveness of the antibody responses 
are further retarded by the swift genetic changes in the viral envelope protein that allow the 
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virus to escape antibody recognition (Richman et al., 2003).  The CD8+ T cells continue to 
suppress the virus throughout, and the specificity of this T cell response evolves in response to 
changes in the envelope protein sequence (Koup et al., 1994).  However, HIV infection is 
established indefinitely in all patients and is regarded as relently progressive albeit a small 
fraction of cells are infected at any point in time and the HIV reservoir established early on is 
not eradicated (Chun et al., 1998).  Thus, the HIV window of vulnerability is only as long as it 
takes for the virus to infect a pool of latently infected cells, a strategy that almost all other viral 
infections do not utilize.  As such, this permanent reservoire of the virus is a perceived obstacle 
of a successful vaccination. 
Humoral Immunity 
Various studies have shown the importance of broadly neutralising antibodies in protecting 
subjects from HIV infection (Baba et al., 2000; Mascola et al., 2000; Burton et al., 2004; 
Barouch et al., 2013; Buchbinder et al., 2014; Goepfert et al., 2014).  As such, early efforts to 
develop an effective vaccine focused on the same strategy deployed in the vaccine against 
hepatitis B, whereby recombinant forms of the viral envelope were genetically engineered in 
order to target the production of neutralising antibodies in hopes that the antibodies would 
recognise HIV virons by their envelope proteins and clear them before infection became 
established (Johnston & Fauci, 2007).  Soluble forms of gp120, all or pieces of the uncleavded 
gp160 precursor protein were tested for safety and immunogenicity in more than 20 phase 1 
clinical trials (Spearman, 2006; Hoffenberg et al., 2013).  These subprotein vaccines failed to 
protect high risk populations (high risk women and MSM in North America and the 
Netherlands, and injection drug users in Thailand)  from infection in two phase 3 trials (Flynn 
et al., 2005; Pitisuttithum et al., 2006).  A possible explanation as to why induction of 
antibodies able to neutralise primary isolates was unsuccessful by gp120 revolves around the 
fact that the envelope on the virion exists as a trimer and the conserved, immunogenic regions 
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of the monomer are blocked in the native trimer (Sanders et al., in press; Kwong et al., 1998; 
Wyatt et al., 1998; Merk & Subramaniam, 2013).  The envelope peptide is covered with 
numerous N-linked glycans and it undergoes conformational changes when it binds to the cell-
surface CD4 receptor (Sanders et al., in press; Chen et al., 2005; Merk & Subramaniam, 2013). 
These conformational changes then expose sequences that are highly variable, as mentioned 
before.   
Recent studies have been conducted with the aim to induce neutralising antibodies based on 
the mutational changes of the virus (Sanders et al., in press; Li et al., 2007; Doria-Rose et al., 
2014).  In a small group of HIV-1 infected subjects, the activity of broadly neutralising 
antibodies has been identified and shown to be directed against conserved regions of the Env 
glycoprotein (Li et al., 2007).  One such conserved region is membrane-proximal external 
region (MPER) on the gp41 protein (Haynes et al., 2005).  This region is the target of 2F5 and 
4E10, MPER-specific broadly reactive monoclonal antibodies.  These are difficult to elicit via 
vaccination due to immunoregulation and tolerance control, the acquisition of the epitope in 
the membrane, and transient exposure of the epitope during viral entry (Haynes et al., 2005; 
Frey et al., 2008; Sun et al., 2008).   
The Thai RV144 trial demonstrated vaccine-induced IgG antibody activity against the first and 
second variable domains (V1V2) of Env was associated with lower risk of HIV infection but 
IgA against Env was directly linked to greater risk of infection (Haynes et al., 2012; Rolland 
et al., 2012; Tomaras et al., 2013; Tomaras & Plotkin, 2017).  While V1V2 antibodies are not 
broadly neutralizing, they appear to mediate antibody-dependent cell-mediated cytotoxicity 
(ADCC) and when Env-specific IgA levels are low, these V1V2 antibodies were found to be 
inversely correlated with the risk of infection (Pollara et al., 2011; Bonsignori et al., 2012; 
Montefiori et al., 2012; Liao et al., 2013; Tomaras & Plotkin, 2017).  Studies have 
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demonstrated that ADCC activity plays a role in SIV control and protection in nonhuman 
primate models (Gómez-Román et al., 2005; Barouch et al., 2012; Smalls-Mantey et al., 2012).  
The importance of a protein immunogen, such as Env, in eliciting an ADCC response has been 
shown previously, whereby ADCC was identified in the sera of rhesus macaques after 
immunization with an Env protein (Chege et al., 2017) 
Cellular Immunity 
CD8+ cytotoxic T lymphocytes are the key effectors of cellular immunity; these cells recognize 
the viral peptides presented by the major histocompatibility complex (MHC) on virally-
infected cells (Janeway et al., 1997).  These CTLs proliferate in the blood in order to contain 
the viremia during natural infection with HIV-1, but they are unable to eliminate viremia 
(Hansen et al., 2011, 2013; McMichael & Koff, 2014).  This is due to the fact that vaccine-
elicited T cells would not emerge and accumulate fast enough in the early stages of infection 
(Mattapallil et al., 2006).  The disease is accelerated and viremia increases without a plateau 
stage in monkeys depleted of CD8+ cells, but when CD8+ cells were reintroduced, the viremia 
was suppressed (Schmitz et al., 1999).  However, a study in SIV-challenged nonhuman 
primates has shown that some T cell vaccines may have the potential to provide protection or 
enable the immune system to clear an estabilished viral infection  (Hansen et al., 2013). 
Another foreseeable obstacle is the high probability that the candidate HIV vaccine sequences 
are not correlated with that of the infecting. HIV-1 viral sequences can vary up to 20% and a 
10% variance in viral sequence from the sequence used to prime the CTLs has a 30–50% 
chance that these lymphocytes will not recognise the virus (McMichael & Koff, 2014). 
1.3.4 Vaccine-induced Th1 immunity 
 As demonstrated, effective HIV vaccine-induced immune responses would need to 1) include 
functional antibodies that are produced by B lymphocytes and are able to specifically bind to 
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HIV proteins, and 2) generate CD8+ T lymphocytes that would restrict the spread of HIV 
infection by being able to recognise and kill infected CD4+ T cells early on in the infection 
cycle, as well as secreting antiviral cytokines (Walker, Ahmed & Plotkin, 2011).  However, 
both the generation of these responses is, in part, mediated by growth factors and signals given 
by CD4+ T helper (Th) cells (Bacchetta, Gregori & Roncarolo, 2005).  These helper 
lymphocytes are generally divided into T helper 1 (Th1) and T helper 2 (Th2) types, effectors 
that are controlled by regulatory T cells (Treg) to maintain and differentiate immunity 
(Bacchetta, Gregori & Roncarolo, 2005).   
T helper 1 (Th1) cells produce IFN-γ, TNF-α, IL-2, and IL-3 all the while supporting activation 
and differentiation of B cells, CD8+ T cells and macrophages.  Vaccines able to elicit robust 
cell-mediated immunity are thought be the most promising for control of infections by many 
intracellular viruses, including HIV (Hansen et al., 2011).  
1.3.5 Vaccine trials 
Vaccines undergo three phases of trials; phase 1 and 2 focus on vaccine safety and 
immunogenicity, and phase 3 delves into the efficacy of the vaccine.  In the last two decades, 
four HIV vaccine efficacy trials (shown in Figure 1.3) have provided invaluable information 
about host immune protection desired and required.   
VaxGen 
The first two phase 3 clinical trials of a VaxGen Corp. HIV vaccine were undertaken in 1998.  
This vaccine was a gp120 subunit immunogen in an alum adjuvant suspension.  In the phase 1 
and 2 trials, it was found to generate only limited levels of neutralizing antibodies.  In the phase 
3 clinical trials, the vaccine had no protective efficacy in the men who have sex with men 
(MSM) population, nor in the injecting drug user population (Gilbert et al., 2005; The rgp120 
HIV Vaccine Study Group, 2005; Pitisuttithum et al., 2006).   
Chapter 1 – Literature Review 
14 
 
The STEP Trial 
The STEP trial, initiated in 2005, was the next HIV vaccine trial to evaluate a vaccine 
engineered to activate a T cell-mediated immunity.  As expected, this immunogen, in a 
recominant adenovirus (Ad5) vector, induced strong T cell responses to HIV proteins as 
determined by ELISPOT and flow cytometry assays but failed to reduce acquisition or long-
term control of post-infection viremia (Buchbinder et al., 2008).  It was later shown in a study 
that human leukocyte antigen (HLA) alleles that were common in the STEP study cohort 
restricted the Gag amino acid 84 site that incorporated in several epitopes in the vaccine 
(Rolland et al., 2011).  The study subjects that had this specific HLA type, as well as those that 
had a robust CD8+ T cell response to Gag and Nef HIV epitopes were able to elicit an immune 
response against the virus in vivo.  This study also demonstrated that subjects that were both 
uncircumsized and immune to Ad5 had an increased risk of HIV infection in the first 18 months 
after receiving the vaccine when compared to the placebo group.  However, this risk decreased 
and equaled that of the placebo group after the 18 month mark.  The reasons for this 
phenomenon remain unknown (Rolland et al., 2011).  
The RV144 Trial 
The RV144 trial, initiated in 2003, set out to evaluate the protective efficacy of a prime-boost 
combination vaccine in Thailand.  The vaccine is combination of envelope protein subtype B 
and E and a canary poxvirus vector ALVAC-HIV expressing HIV-1 subtype B protease and 
Gag, and a fusion subtype B and E envelope.  When the results were reported in 2009, the trial 
demonstrated a 31.2% reduction in the acquisition of HIV infections in the heterosexual male 
and female populations that received the vaccine regimen as opposed to the placebo group after 
3.5 years (Rerks-Ngarm et al., 2009).  Thus, this trial was proof that a correctly designed and 
administered vaccine could have the potential to prevent new HIV-1 infections.   
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Expanding on this, vaccine recipients from the RV144 trial that were still  HIV-1 negative were 
reimmunized 6–8 years later with AIDSVAX B/E gp120 alone, ALVAC-HIV alone, or a 
combination of ALVAC-HIV and AIDSVAX B/E gp120 in the RV305 trial.  This was found 
to boost memory B cells.  Antibodies elicited were shown to be reactive to the gp140 Env 
trimer (Easterhoff et al., 2017). 
HVTN 505 
The HIV Vaccine Trial Network (HVTN) 505 trial commenced participant enrolment in June 
2009 and tested another variation of the rAd5 vaccine (Hammer et al., 2013).  The regimen 
consisted of three doses of a plasmid containing non-HIV DNA and certain HIV genes as a 
prime, followed by one boost of rAd5 expressing HIV Env and viral structural antigens 
(Hammer et al., 2013).  The study restricted enrollment to circumcised MSM who who were 
screened for Ad5 antibodies prior to the trial (Hammer et al., 2013).  This was due to the lack 
of risk to this demographic as shown by the STEP trial (Duerr et al., 2012).  Unfortunately, the 
HVTN 505 trial was stopped prematurely as it met futility criteria, whereby both the 95% 
confidence intervals for vaccine efficacy and the difference in viral load were below their 
respective design limit of reductions of 50% and 1.0 log10 copies per mL, respectively (Hammer 
et al., 2013). 
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Figure 1.3 - Vaccine trials over the past decade.  The past decade has seen 5 highly publicised HIV vaccine 
trials; VaxGen USA, VaxGen Thai trial, STEP trial, RV144 Thai trial and HVTN 505 trial. These trials have had 
varying levels of success, with the RV144 trial having the greatest efficacy and thus receiving the most attention 
from the scientific community (Source: Corey et al., 2011). 
 
Trials in South Africa 
In South Africa, there have been 18 trials conducted (table 1.1).  Included in these are the 
clincal trials of two vaccines developed at the University of Cape Town; SAAVI DNA-C2 and 
SAAVI MVA-C.  A phase 1 clinical study (HVTN 073E/SAAVI 102E) was conducted in 
South Africa and the United States using the SAAVI DNA-C2 and SAAVI MVA-C vaccines 
in a DNA/MVA prime-boost regimen.  An additional boost of a V2-deleted envelope subunit 
HIV-1C protein vaccine adjuvanted with MF59 was administered to improve HIV Env-specific 
antibody responses.  As well as being judged to be safe and well tolerated, the DNA-MVA 
regimen elicited CD8+ T cell responses in 32% of the participants and CD4+ T cell responses 
in 74% of the participants, which was further increased to 87% by the protein boost (Gray et 
al., 2016).  Tier 1 HIV-1C neutralizing antibody responses as well as durable Env binding 
antibodies were elicited by 100% of the participants (Churchyard et al., 2016; Gray et al., 2016) 
The SAAVI DNA-C2 vaccine is an equimolar mixture of 2 DNA plasmids, one of which 
expressed a polyprotein designated Grttn, consisting of translational fusions of HIV-1 
subtype C Gag, reverse transcriptase (RT), Tat and Nef.  The other plasmid expressed a 
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truncated envelope protein (Env gp150).  The genes included were based on the closeness to a 
South African HIV consensus sequence and were inserted for optimal expression as well as to 
safety by restricting some functionality of the virus (Burgers et al., 2006).  The other vaccine, 
SAAVI MVA-C was based on a modified smallpox virus vaccine; modified vaccinia Ankara 
(MVA) and contained the same HIV genes as SAAVI DNA-C2.  Both vaccines have shown to 
induce robust T cell immune responses in mice, as well as nonhuman primates, when coupled 
in prime-boost immunizations in pre-clinical testing (Burgers et al., 2006, 2008; Shephard et 
al., 2008; Chege et al., 2017).  A study conducted by Chege and colleagues (2017) showed that 
a single vaccination with SAAAVI MVA-C concurrently with HIV gp140 Env protein in 
rhesus macaques elicited both T cell-mediated and Env-specific antibody responses (Chege et 
al., 2017).   
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Table 1. 1  Details of HIV vaccine trials conducted in South Africa (Source: International AIDS Vaccine 
Initiative, 2016). 
Phase Trial ID Status Prime Boost 1 Boost 2 Strategy 
I Extension HVTN 
073E/SAAVI 102 
Completed Sub C gp140     Protein 
I HVTN 040 Completed AVX101     Viral vector- 
Alphavirus 
I HVTN 
050/Merck 018 
Terminated MRKAd5 
HIV-1 gag 
    Viral vector- 
Adeno 
I HVTN 059 Completed AVX101     Viral vector- 
Alphavirus 
I HVTN 073 Completed  SAAVI DNA-
C2 
SAAVI MVA-C   DNA, viral 
vector- Pox 
I HVTN 083, 
SAAVI 103 
Ongoing SAAVI MVA-
C 
SAAVI DNA-C2 Oligomeric 
gp140/MF59 
Viral vector- 
Pox, DNA, 
protein 
I HVTN 097 Ongoing ALVAC-HIV 
vCP1521 
AIDSVAX B/E   Viral vector- 
Pox, Protein 
I/II HVTN 100 Ongoing ALVAC-HIV-
C (vCP2438) 
Bivalent Subtype 
C gp120/MF59 
  Viral vector- 
Pox, protein 
I HTVN 116 Ongoing VCR-
HIVMAB0 60-
00-AB 
VRCHIV/MAB08 
0-00-AB 
  Passive 
immunization, 
passive 
immunization 
II HVTN 204 Closed to 
follow-up 
VRC-
HIVDNA0 16-
00-VP 
VRC-HIVADV0 
14-00-VP 
  DNA, viral 
vector- Adeno 
IIb HVTN 503 
(Phambili) 
Terminated MRKAd5 
HIV-1 
gag/pol/nef 
    Viral vector- 
Adeno 
IIb HVTN 702 Scheduled ALVAC-HIV-
C (vCP2438) 
Bivalent Subtype 
C gp120/MF59 
  Viral vector- 
Pox Protein 
IIb HVTN 703 AMP Ongoing VRC-
HIVMAB0 60-
00-AB 
    Passive 
immunization 
I IAVI 011 Completed MVA.HIVA     Viral vector- 
Pox 
II IAVI A002 Completed TgAAC09     Viral vector- 
Adeno-
associated virus 
I IAVI B003 Completed Ad26.EnvA-01 Ad35-ENV   Viral vector- 
Adeno, zviral 
vector- Adeno 
I IMPAACT P1112 Ongoing VRC-
HIVMAB0 60-
00-AB 
    Passive 
immunization 
I/II IPCAVD009 Ongoing Ad26.Mos.HIV 
Trivalent 
Gp140 DP MVA 
mosaic 
Viral vector- 
Adeno, protein, 
viral vector- 
Pox 
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1.4 Helminth infections 
1.4.1  General background of parasitic helminths 
Parasitic helminths are parasitic worms that reside within a host for nourishment and 
protection, while causing poor nutrient absorption and illness in the host (Pullan & Brooker, 
2008).  The groups of worms that are clinically relevant are classified by their internal and 
external morphology as eggs, larvae and adults.  There are two major phyla of helminths; 
1) Nematodes, or phylum Nematoda (roundworms), which include the major intestinal 
worms (soil-transmitted helminths, such as hookworms and ascarids) and the filarial 
worms that cause lymphatic filariasis (LF) and onchocerciasis.  Nematodes are 
dioecious, with cylindrical bodies that have a cuticle after their larval stage, and a 
complete digestive system throughout their life cycle.  
2) Platyhelminths, phylum Platyhelminthes (flatworms), which include the flukes 
(trematodes), such as the schistosomes, and the tape-worms (cestodes).  These worms 
have a soft body with tegument and an incomplete digestive system but without coelom.  
Platyhelminths are hermaphroditic except for schistosomes.  
1.4.2  Prevalence and global distribution 
It is estimated that more than two million people are infected with a helminth globally, and 
almost half live in developing regions of sub-Saharan Africa, Asia, and the Americas and are 
often chronically infected with more than one helminth (shown in Figure 1.4) (Elliott et al., 
2007; Hotez et al., 2008; Means et al., 2016).  The most common human helminth infections 
are the intestinal helminths, such as ascariasis, trichuriasis, and hook-worm, followed by 
schistosomiasis and LF (Hotez et al., 2008).  This great burden of helminth infection is further 
compounded by the fact that in sub-Saharan Africa and elsewhere, helminthiases are frequently 
co-endemic with HIV (Borkow & Bentwich, 2008; Hotez et al., 2008; Secor, 2012; Means et 
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al., 2016).  Thus, it is likely that an individual infected with HIV is also infected with one or 
more parasitic worm and vis a vis.  Helminths cause an immunomodulatory response in an HIV 
infected host, which increases the survival rates of the parasite and thus the subsequent 
establishment of chronic helminth infections (Bethony et al., 2006; Downs & Fitzgerald, 2016; 
Storey et al., 2017).  A prospective study by Kroidl et al. (2016) demonstrated a significantly 
increased risk (almost double) of acquiring HIV for helminth-infected adults and adolescents 
in rural Tanzania (Downs & Fitzgerald, 2016; Kroidl et al., 2016). 
 
Figure 1.4 - Global prevalence and distribution of helminths in 2015 (Source: WHO, 2016 
http://apps.who.int/neglected_diseases/ntddata/sth/sth.html)  
 
More than 85% of infections with schistosomes specifically are in Africa.  Schistosomes are 
predicted to have infected 50% of the population in high-risk rural communities (Bustinduy et 
al., 2014).  Schistosomiasis is conservatively reported to infect more than 230 million people 
globally, with more than 66.5 million people receiving treatment in 2015 (Colley et al., 2014; 
WHO, 2017).   
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1.4.3  Prevalence of helminth infections in children 
Children have been found to have the highest prevalence of helminth infections of other age 
group (Davis et al., 2014; Shumbej et al., 2015).  A study conducted by Adedoja and colleagues 
(2015) assessed the parasitic burden amongst children between the ages of 4 and 15 in rural 
Nigeria.  As shown in table 1.2. they reported that more than 25% of children surveyed within 
this age group had more than one parasitic infection with S. haematobium, a hookworm and/or 
a tapeworm (Adedoja et al., 2015).   
Table 1. 2 Prevalence of single and double parasitic infection among children (Source: Adedoja et al., 
2015) 
 Prevalence of single infection (%) 
Age Group No. SH HW HN 
4-9 445 182 (40.9) 86 (19.3) 45 (10.1) 
10-15 572 270 (47.2) 143 (35) 55 (9.6) 
Total 1017 452 (44.4) 229 (22.5) 100 (9.8) 
p-value  0.049 0.034 0.83 
     
 Prevalence of double infection (%) 
Age Group No. SH + HW SH + HN HW + HN 
4-9 445 60 (13.5) 17 (3.8) 11 (2.5) 
10-15 572 104 (18.2) 32 (5.6) 20 (3.5) 
Total 1017 164 (16.1) 60 (5.9) 32 (3.1) 
SH = S. haematobium 
HW = Hookworm 
HN = Hymenolepis sp. 
 
Reflecting this trend, Schistosoma has higher reported infection rates in children than in adults 
(Gryseels et al., 2006).  The disease burden amongst children in high risk areas has been 
historically difficult due to the fact that areas of high prevalence of schistosomiasis 
transmission are usually where healthcare facilities are inadequate, so surveillance of the 
disease is mostly defunct and has thus far failed to monitor this age group.  Regardless, routine 
parasitological screens miss some low-level infections as the parasite detection levels have 
been shown to be too high (Berhe et al., 2004; Wilson et al., 2006).  Some studies that have 
been able to quantify the prevalence and intensity of infections in younger children demonstrate 
that schistosomiasis, either urinary (caused by Schistosoma haematobium) or intestinal (caused 
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by Schistosoma mansoni), can be common (Bosompem et al., 2004; Odogwu et al., 2006; 
Verani et al., 2011).  In the later study, 90% of children under the age of 10 and 14% under the 
age of 1 year old surveyed in a rural Kenyan town were infected with S. mansoni (Verani et 
al., 2011).  
The age distribution of infection rates and intensity has been attributed to increased frequency 
of contact with contaminated water among school-aged children and adolescents, whereas 
older adolescents and adults generally have less contact with the same water and have 
developed an acquired protective immunity against infection (Verani et al., 2011)  The intensity 
of S. mansoni infection in the different age groups is shown in table 1.3. 
Table 1. 3 Estimated number of individuals with morbidity or pathology due to S. mansoni infection by age 
group in sub-Saharan Africa in millions (90% confidence interval) (Source: van der Werf et al., 2003) 
Category Pre-school children School children Adults Total 
At risk of infection 65 152 177 393 
Infected 4.7 25 23 54 
Diarrhoea in last 2 weeks 0.034 (0.00–0.72) 0.42 (0.0–3.6) 0.32 (0.0–3.5) 0.78 (0.0–7.8) 
Blood in stool in last 2 weeks 0.24 (0.16–0.69) 2.3 (1.6–4.1) 1.9 (1.3–3.7) 4.4 (3.0–8.3) 
Hepatomegaly (MSL) 0.076 4.0 3.8 8.5 
Splenomegaly [0.61] [2.9] [2.8] [6.3] 
Ascitis [0] [0] [0.29] [0.29] 
Haematemesis ever [0] [0] [0.93] [0.93] 
[ ] use with caution, risk for confounding (splenomegaly) or estimations derived from limited literature data 
(ascitis and haematemesis). Intervals could be calculated for diarrhoea and blood in stool. 
 
1.4.4 Schistosoma mansoni – a prototype parasitic helminth 
Infection of humans with helminths of the Schistosoma genus causes schistosomiasis (also 
termed bilharzia), which displays many characteristics of a classical helminthic worm 
infection.  The main species that cause diseases in humans are S. haematobium, S. mansoni 
and S. japonicum.  Adult schistosome worms are grey, 7–20 mm long and cylindrical with two 
terminal suckers, a complex tegument, a blind digestive tract and a reproductive system.  
However, schistosomes, unlike other trematodes, are dioecious (Gryseels et al., 2006).  To 
reproduce, the longer, thinner female permanently embeds herself within the groove of the 
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male worm.  These schistosomes live within the perivesical (only S. haematobium) or 
mesenteric (all other species) venous plexus.  Once there, the females will produce hundreds 
to thousands of eggs per day.  Each ovum contains a ciliated miracidium larva, which helps the 
eggs to migrate into the lumen of the bladder (only S. haematobium) or the intestine (all other 
species).  The eggs are then excreted in the urine (only S. haematobium) or faeces (all other 
species) (Centers for Disease Control, 2012).  When the eggs make contact with water, the egg 
can  hatch and rid itself of the miracidium and is then able to infect the intermediate host, 
freshwater snails such as Biomphalaria glabrata, as miracidia (Gryseels et al., 2006).  
Thereafter, the miracidia replicate asexually into sporocysts and develop into cercarial larvae 
with embryonic suckers and a bifurcated tail to aid in swimming once the cercariae are shed 
from the snail host.  This shedding process is initiated by light.  The released cercariae are then 
able to penetrate human skin and gain access to circulatory system and eventually end up in 
the portal vein where they mature into adults and begin the cycle again, as shown by Figure 1.5.  
The lifespan of an adult worm is around 3–5 years but it can be as long as 30 years (Gryseels 
et al., 2006).  
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Figure 1.5 – Life cycle of Schistosoma species that commonly infect humans; S. mansoni, S. japonicum and 
S. haematobium A: paired adult worms (sturdy male holding slender female). B: eggs (left to right, S 
haematobium, S mansoni, S japonicum). C: ciliated miracidium. D: intermediate host snails (left to right, 
Oncomelania, Biomphalaria, Bulinus). E: cercariae (Source: Colley et al., 2014).  
 
Acute schistosomiasis, or Katayama fever, is a feverish syndrome and a hypersensitivity 
reaction raised against mobilized schistosome parasites in the blood (Bottieau et al., 2006).  
Whereas chronic schistosomal disease affects individuals with long-standing infections, and a 
reaction to the eggs released by the parasite, rather than to the parasite themselves (Gryseels et 
al., 2006).  These eggs get trapped in the liver, spleen, lungs or cerebrospinal system (Gryseels 
et al., 2006).  The resulting immunopathological reactions against schistosome eggs trapped in 
the tissues lead to inflammatory and obstructive disease in the urinary system (S. haematobium) 
or intestinal disease, hepatosplenic inflammation, and liver fibrosis (S. mansoni, S. japonicum).  
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The cytokine IL-17, secreted by T helper 17 (Th17) cells, has been described to have a role in 
the production of granulocytes as part of the inflammatory response against Schistosoma 
soluble egg antigen (SEA), the development of liver granulomas as well as affect liver fibrosis 
(Matsuzaki & Umemura, 2007; Sharma et al., 2014; Nady et al., 2016).  Another cytokine 
secreted by Th17, IL-22, has been reported to protect against liver fibrosis and cirrhosis in 
chronic infections as well as repress inflammation in autoimmune diseases (Matsuzaki & 
Umemura, 2007; Wilson et al., 2010; Sertorio et al., 2015).  However, the role of IL-22 in a 
schistosomal infection is unclear (Nakae et al., 2007).  The roles of Th17 cytokines on 
S. haematobium infections in humans and S. mansoni infections in mice have been investigated 
in some studies (Mbow et al., 2013; Nady et al., 2016).  The immunological role of Th17 
cytokines in mice infected with S. mansoni has been shown to be mediated by dendritic cells 
(not basophils, as previously thought) and the expression of CD209a by these cells (Ponichtera 
et al., 2014; Sharma et al., 2014).  Thus, a study by Nady and colleagues (2016) showed that 
IL-17 can accelerate SEA-induced granuloma formation and as well as attenuate granulocyte 
functions in S. mansoni infected humans, while IL-22 conversely can attenuate formation of 
granulomas but enhanced granulocyte functions (Nady et al., 2016). 
1.4.5 Helminth immunomodulation 
Since 1989, T cells have been differentiated into two major subsets, T helper 1 (Th1) and T 
helper 2 (Th2) cells.  Detecting the different subsets can be done by measuring the production 
of specific cytokines (IFN-γ for Th1 and IL-4 for Th2) (Mosmann & Coffman, 1989; Hirahara 
& Nakayama, 2016).  Signalling the induction of either Th1 or Th2 differentiation is done by 
IL-12 and IL-4 respectively.  The Th1 response has been shown to be imperative for host 
defence against intracellular pathogens such as Leishmania major (Reiner & Locksley, 1995; 
Hirahara & Nakayama, 2016).  Conversely, the Th2 response has been demonstrated to be vital 
for the clearance of helminthic parasites such as Nippostrongylus brasiliensis (Pulendran & 
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Artis, 2012; Hirahara & Nakayama, 2016).  Thus, classification of the immune responses that 
occur in the elimination of microbial pathogens can be done by detecting either Th1 or Th2 
differentiation (Hirahara & Nakayama, 2016). 
As shown in Figure 1.6, chronic helminth infections can be characterized by an early Th1 
response that switches to robust Th2 response when eggs are produced, as well as an overall 
down-regulated immune system (Pearce & MacDonald, 2002; Colley et al., 2014).  Type 2 
immunity has evolved specifically to deal with helminths and similar types of pathogens 
(Pearce et al., 1991; Lundie et al., 2016).  Helminths are known to skew the immune response 
towards Th2, characterized by Th2 related cytokines, that typically include IL-4, IL-5 and IL-
13 that induce B lymphocytes to switch to IgE antibody production (Pearce & MacDonald, 
2002; Mulu et al., 2015).  This immunity involves the rapid stimulation and engagement of 
cells of both the innate (eosinophils and basophils) and adaptive (CD4+ T cells that commit to 
the Th2 pathway) immune systems (Voehringer, Shinkai & Locksley, 2004).  Despite the broad 
variation of characteristics between different helminth groups, most helminths induce similar 
adaptive immune responses in their human host.  Cells of the innate and adaptive immune 
systems that are involved in type 2 immunity are able to synthesize type 2 cytokine IL-4, which 
directly and indirectly mediates the reactions that are considered to be indicative of helminth 
infection such as IgE production (Voehringer, Shinkai & Locksley, 2004; Mulu et al., 2015).  
Chronic helminth infection has been shown to induce Th2 biasing, needed for immune defence 
against parasitic worm infections, as well as IL-4- with IL-10-mediated immune suppression, 
which compromises cell-mediated Th1 immune responses (Nutman, Kumaraswami & Ottesen, 
1987; Grzych et al., 1991; Pearce et al., 1991, 2004, Araujo et al., 1994, 1996; Sartono et al., 
1995; Maizels & McSorley, 2016).  Many studies have postulated that Th1 and Th2 responses 
are mutually exclusive (Randolph et al., 1999; Maizels & Yazdanbakhsh, 2003; Borkow & 
Bentwich, 2008; Mcsorley & Maizels, 2012). 
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Figure 1.4 - Progression of the immune response during schistosomal infection.  During the course of 
infection, immunity progresses through at least three phases.  In the first 3–5 weeks, during host exposure to 
immature parasites, the dominant response is T helper 1 (Th1) type.  The parasites mature, mate and begin to 
produce eggs at weeks 5–6, and the response morphs; the Th1 decreases and is replaced with a robust Th2 
response, induced primarily by parasitic egg antigens.  During the progression of the chronic stage, the Th2 
response is regulated and controlled. (Source: Pearce & MacDonald, 2002)   
 
The Th2-type responses appear to have a critical role in moderating the severity of chronic 
disease.  The main Th2 cytokine that is responsible for hepatic fibrosis is IL-13.  This has been 
proven in schistosome-infected mice whereby IL-13 is either absent (Il13−/−)(Fallon et al., 
2000), ineffective (IL-4 receptor α-chain-knockouts; IL4rα −/− )(Jankovic et al., 1999) or 
neutralized (by treatment with soluble IL-13Rα2–Fc (Chiaramonte et al., 1999)) were unable 
to develop the severe fibrosis that is normally associated with this stage of infection and as 
such, these mice were generally able to survive longer (Fallon et al., 2000).  Alternatively, 
mediators that are generally associated with Th1 immunity, such as IFN-γ, IL-12 and TNF-α 
have been shown to prevent IL-13-mediated fibrosis in the mouse model (Hesse et al., 2001).  
Expanding on this, a paper by Yin and colleagues (2012) reported that schistosome infection 
induced high expression of IL-4 and IL-13 in mice, but after vaccination with their candidate 
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vaccine developed by their colleagues, the expression of the Th2 cytokine, IL-13, was 
decreased and replaced by Th1 cytokines such as TNF-α.  However, the authors also showed 
that there was no change in expression of Th2-like IL-4 and Th1-like IFN-γ (Yin et al., 2012).   
Recent studies have shown that tuft cells are an important source of IL-25, a cytokine also 
necessary to mount a type 2 immune response (von Moltke et al., 2015; Gronke & Diefenbach, 
2016; Howitt et al., 2016).  A new regulatory circuit involving IL-25 production by tuft cells 
and group 2 innate lymphoid cells (ILC2) has been described, which affects intestinal stem cell 
differentiation favouring the generation tuft cells as well as goblet cell hyperplasia which has 
been shown to be effective in the expulsion of helminth worms such as N. brasiliensis (von 
Moltke et al., 2015; Gronke & Diefenbach, 2016). 
1.4.6 Helminthiasis and interaction with vaccines and other pathogens 
Due to high HIV prevalence in Africa, as stated previously, successful future HIV vaccines 
will be most needed in Africa. (Barouch, 2008).  However, there is a large prevalence of 
helminth infections in SSA (Chan, 1997; de Silva et al., 2003; Van Der Werf et al., 2003; Hotez 
et al., 2004; Utzinger & Keiser, 2004; Obuku et al., 2016).  As stated before, helminth 
infections have been shown to skew the immune system of human as well as animal hosts to a 
Th2 type and to suppress the Th1 immune responses (Nutman, Kumaraswami & Ottesen, 1987; 
Grzych et al., 1991; Pearce et al., 1991, 2004, Araujo et al., 1994, 1996; Sartono et al., 1995; 
McKee & Pearce, 2004; Lundie et al., 2016).  Helminth-infected people may not be able to 
generate the required immune responses   
As such, in the presence of chronic helminthic infections, Th1 responses and cytotoxic T cell 
responses elicited by vaccines may be attenuated, hence vaccine efficiency would be reduced 
(Bentwich et al., 1999; Borkow & Bentwich, 2000; Thomas & Harn, 2004; Obuku et al., 2016).  
For example, a recent study published in 2014 that investigated the effect of Nippostrogylus 
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brasiliensis on the natural and vaccine-mediated immunity to Salmonella (Bobat et al., 2014).  
These authors found that mice infected with N. brasiliensis prior to immunization with a 
subunit vaccine of Salmonella porins developed a higher bacterial load of Salmonella after 
Salmonella challenge, when compared to the helminth-uninfected and vaccinated group (Bobat 
et al., 2014).  A similar mouse study by Haben, Hartmann and Breloer (2014) investigated the 
impact of an infection with Litomosoides sigmodontis at different life stages on the efficacy of 
an experimental vaccine against Plasmodium berghei.  This study demonstrated that the 
helminth infection was able to attenuate accessory T helper cells, thus suppressing the 
antibody-producing B cells and ultimately completely suppressing humoral antibody responses 
to the vaccine.  This antibody suppression was more evident in mice that had been previously 
infected with the helminth, or had a current chronic stage infection (Haben, Hartmann & 
Breloer, 2014). 
Clinical and pre-clinical research has suggested that the negative impact of the immune 
deviation of reduced Th1-type reduces responses to BCG and tetanus toxoid vaccine on 
populations living in schistosome predominant areas (Sabin et al., 1996; Elias et al., 2005).  In 
a pre-clinical study by Elias and colleagues (2005), mice vaccinated with BCG prior to S. 
mansoni infection significantly expressed the TB virus, suggesting the protective efficacy of 
the BCG vaccine was reduced by S. mansoni infection possibly via polarization of the general 
immune responses to the Th2 profile.   
These pre-clinical findings are supported by an earlier clinical study conducted on human 
subjects in Brazil, whereby subjects infected with S. mansoni were evaluated for their ability 
to mount Th1 IFN-γ responses to a tetanus toxoid (TT) vaccine as compared to an uninfected 
control group (Sabin et al., 1996).  The resulting data reported that the IFN-γ produced in 
response to TT was significantly diminished in the helminth-infected group (Sabin et al., 1996).  
A similar study found that patients infected with Ascaris lumbricoides mounted lower Th1 
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(IFN-γ and IL-2) responses to cholera toxin B subunit vaccine as opposed to uninfected patients 
(Cooper et al., 2001).  This study also showed that if parasitic treatment with albendazole was 
administered before the vaccination, IL-2 production to the vaccine was significantly enhanced 
compared with the placebo group, whereas IFN-γ production was not restored (Cooper et al., 
2001).   
Continuing along the treatment of helminth infection, Da’dara and Harn (2010) investigated 
the immunogenicity of a HIV-1 DNA vaccine in mice that were infected with S. mansoni and 
then treated with praziquantel prior to vaccination.  In this study, it was found that the 
antiparasitic treatment completely restored the ability of mice to induce robust vaccine-specific 
T cell responses (Da’dara & Harn, 2010).  Surprisingly, this study also showed that IL-10 (an 
immunosuppressive cytokine) in treated mice was higher than the mice that were infected with 
the helminth (Da’dara & Harn, 2010).  This suggests that the IL-10 cytokine should not be used 
as a predictive marker of immune status for T cell based vaccines (Da’dara & Harn, 2010). 
Further evidence to show the negative impact of helminthiasis on Th1 immune responses 
comes from a coinfection study with malaria in a mouse model.  In the study, the murine 
immune responses to malaria, Plasmodium chabaudi, showed that coinfection with 
Heligmosomoides polygyrus, a gastrointestinal nematode, resulted in diminished production of 
malaria-specific IFN-γ and IgG2a (Su et al., 2005).  The mice that were coinfected were also 
impaired in their ability to control the malaria infection when compared to the mice that were 
not infected with the helminth (Su et al., 2005).  Actor and colleagues (1993) demonstrated 
that schistosome-infected mice elicited reduced Th1 cytokines, as expected, but that these mice 
also had impaired CTL responses against HIV-1 Env epitopes. It was also shown that these 
helminth-infected mice had a diminished capacity to clear vaccinia in an experimental viral 
challenge (Actor et al., 1993).  These findings were supported by a later study conducted on 
humans whereby S. mansoni-infected HIV positive patients had decreased HIV-specific CD8+ 
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CTL responses as well as an increased number of HIV-specific IL-10 positive CD8+ T cells, 
when compared with HIV positive patients that were not infected with a helminth (McElroy et 
al., 2005).  In contrast, in a study conducted on HIV infected Ugandan fishermen, the 
frequencies of HIV-specific IFN-γ+ IL-2– TNF-α− CD8+ T cells and IFN-γ+ IL-2– TNF-α+ 
CD4+ T cells were significantly increased in HIV and S. mansoni-coinfected fishermen when 
compared with helminth-free HIV positive individuals (Obuku et al., 2016).  The findings in 
this study appear to contradict the theory that S. mansoni downregulated HIV-specific Th1 
responses in HIV and S. mansoni-coinfected human hosts (Obuku et al., 2016).  
In addition to the above, another study by Shollenberger and colleagues (2013) in a mouse 
model showed that on-going helminthiasis does not inhibit an HIV-1 vaccine (Shollenberger 
et al., 2013).  The study demonstrated that the immunogenicity if a HIV-1 Gag vaccine that 
they had developed using Listeria monocytogenes as a vector was not hindered by a S. mansoni 
infection experimentally acquired between initial vaccination and a subsequent boost.  These 
studies demonstrate the feasibility of the theory that helminth infections could devastate the 
immunity elicited by a Th1/CTL-based vaccine, and thus reduce the efficacy of the vaccine 
administered, however the contrasting findings validate the need to conduct further and more 
detailed investigations. 
1.5 Research justification 
1.5.1  Problem identification 
HIV and helminth parasite infection are two of the most widespread infections that are endemic 
to most parts of SSA (World Health Organisation (WHO), 2016).  The development of 
effective affordable HIV vaccines is one of the most cost-effective strategy of controlling the 
HIV epidemic (UNAIDS, 2016b).  This is proposed to be achieved through the development 
of an HIV vaccination regimen that can elicit the induction of potent T cell mediated immune 
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responses to control viral replication in the tissues and disease progression as well as a durable 
humoral immune response (Johnston & Fauci, 2007; Fauci et al., 2008; Ross et al., 2010; 
Cohen & Dolin, 2013).  These types of immune responses are influenced by a T helper cell 
type 1 (Th1) immune response.  However, several studies show that chronic helminth infection 
induces a Th1-Th2 immune imbalance with a predominant Th2 immune response (Sabin et al., 
1996; Elias et al., 2005; Da’Dara et al., 2006; Da’dara & Harn, 2010).   
The majority of individuals living in SSA and other developing countries, especially school-
aged children, are infected with one or more helminth parasites, which result in predominant 
Th2 immune settings (de Silva et al., 2003; Hotez et al., 2004, 2008; Verani et al., 2011; Colley 
et al., 2014). There is little scientific data to inform how candidate HIV vaccines would perform 
in the presence of ongoing helminthiasis.  Important questions that could be asked are: will 
successful future HIV vaccines be equally effective in areas where helminths are endemic?  
Could helminth-induced Th2 responses possibly attenuate the induction of HIV vaccine 
immunity? 
1.5.2  Rationale & use of the animal model 
It is expected that successful future HIV vaccines will be given to infants during childhood 
vaccination programmes to protect them from maternal HIV transmission through 
breastfeeding. It’s also likely that a booster HIV vaccination will be required during 
adolescence to protect them against contracting HIV by sexual transmission (Pathan et al., 
2007; van der Sande et al., 2007; Lu et al., 2009).  Of the 230 million people infected with a 
schistosome, school-going children in rural areas generally have the highest prevalence and 
intensity of infection (Van Der Werf et al., 2003; Verani et al., 2011; Colley et al., 2014).  It 
is therefore important to investigate if infection with helminth parasites would have a negative 
impact on the capacity of candidate HIV vaccines to boost primary responses that were 
generated during childhood vaccinations. This is particularly crucial for SSA and other 
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developing countries where HIV and helminth infections are co-endemic and children are at 
risk for contracting these parasitic worm infections. 
This study will evaluate whether a candidate HIV vaccine regimen shown to induce humoral 
and cellular immune responses is negatively impacted by helminth-induced immune responses.  
The candidate SAAVI MVA vaccine, a T cell vaccine, was demonstrated to induce strong 
cellular responses to Gag, RT and Env following prime-boost immunisations in mice (Shephard 
et al., 2008).  Addition of a HIV-1 Env protein, gp140, to SAAVI MVA vaccination regimen 
has been shown to induce both cellular and robust anti-Env serum antibody responses in a 
rhesus macaque model study (Chege et al., 2017) and clinical trials (Churchyard et al., 2016; 
Gray et al., 2016).  However, unlike the studies by Chege et al. (2017), Churchyard et al. (2016) 
and Gray et al. (2016), the Env protein used here included intact V1/V2 loops.  Schistosoma 
mansoni was chosen as a helminth model parasite due to its availability and established 
protocols in our collaborators facility, as well as the S. mansoni infection model being well 
established in BALB/c mice (Actor et al., 1993; Da’Dara et al., 2006; du Plessis et al., 2013).   
Using a candidate HIV vaccine as a model for combined cell mediated and antibody mediated 
immune responses, generated data will give detailed information on the potential impact of 
chronic helminth infection on the immunogenicity induced by HIV vaccines.  This study will 
also justify further investigation using nonhuman primate models and possibly clinical trials in 
humans impacted by both helminth infections and HIV.  
1.5.3 Hypothesis 
We hypothesize that chronic infection with Schistosoma mansoni will attenuate the capacity of 
a poxvirus/protein HIV vaccine regimen to boost primary HIV vaccine responses. 
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1.5.4 Aims and objectives 
The aim of this study was to investigate whether an ongoing chronic helminthiasis impacts 
negatively on the capacity of candidate HIV vaccine (SAAVI MVA and a subunit HIV 
envelope protein) to mount booster responses in a mouse model.  The objectives are as 
following: 
1. To vaccinate groups of mice with SAAVI MVA concurrently with gp140 Env (subunit 
HIV envelope protein) vaccine formulated with an Alum adjuvant in order to induce 
both cellular and humoral HIV-specific immune responses. 
2. To inoculate half of the mice with Schistosoma mansoni cercariae to induce chronic 
helminthiasis while the control groups remain uninfected (appropriated non-vaccinated 
and infected controls included). 
3. To administer booster vaccinations (appropriate test & control groups) with SAAVI 
MVA-C in combination with gp140 Env after establishment of chronic helminthic 
infection. 
4. Harvest samples/organs from animals and conduct laboratory analyses to elucidate 
resultant cellular and humoral immunity as well as confirm chronic infection. 
5. Compile data and perform statistical analyses
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2.  Materials and Methods 
2.1. General Laboratory Equipment 
All animal work and laboratory experiments were conducted on University of Cape Town 
premises’.  Experimental mice were housed in the animal biosafety level 2 (ABSL2) rooms in 
the Research Animal Facility (RAF) of the Faculty of Health Science.  Schistosoma worm 
parasites were produced from S. mansoni-infected snails that were maintained in the snail 
facility provided by Prof Frank Brombacher of the International Centre for Genomic 
Engineering and Biotechnology (ICGEB) – Cape Town Component.  Laboratory space and 
equipment including fridges, freezers, a CO2 incubator and a class II biosafety cabinet were 
provided by Prof Anna-Lise Williamson of the Institute of Infectious Disease and Molecular 
Medicine (IDM).  The BD LSRII cytometer was provided by the IDM Flow Cytometry Core 
Facility. 
2.2. Materials 
2.2.1.  Vaccine 
The following two HIV-1 vaccines were used in this study: 
1) SAAVI MVA-C; a candidate HIV-1 vaccine that was developed by the research team of 
Prof A-L Williamson at the University of Cape Town, South Africa, as previously described 
(Burgers et al., 2008).  Briefly, the vaccine contains a polygene gag, reverse transcriptase (rt), 
tat, nef (grttnC) and env (gp150CT) genes derived from HIV subtype C vaccine strains Du151 
and Du422 in a single recombinant modified vaccinia Ankara (MVA) virus (Burgers et al., 
2008).  This vaccine was demonstrated to induce strong cellular responses to Gag, RT and Env 
following prime-boost immunisations in mice (Shephard et al., 2008) and nonhuman primates 
(Burgers et al., 2009; Chege et al., 2012, 2017).  This vaccine, together with its DNA counter-
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part were developed for clinical evaluation in a first phase I placebo-controlled clinical trial, 
titled HVTN 073/SAAVI 102, performed on HIV-uninfected healthy adult participants in 
South Africa and the United States of America (Williamson et al., 2012) and has been to be 
immunogenic (Churchyard et al., 2016; Gray et al., 2016).  This trial confirmed the safety and 
immunogenicity of the vaccine in humans as a prime-boost regimen with SAAVI DNA-C 
priming. A research lot of SAAVI MVA-C, which was manufactured by Therion Biologics 
Corporation (Cambridge, MA, USA; now defunct) under Good Manufacturing Practices 
(GMP) was used in the current study.   
2) HIV gp140 Env protein vaccine; gp140 (TV-1)(HIV-1/Clade C) protein was obtained from 
Immune Technology.  This protein was derived from a South African HIV subtype C primary 
isolate (TV-1) (Lian et al., 2005).  This was included in the vaccination regimen to mimic the 
robust anti-Env serum antibody responses as shown previously in a rhesus macaque model and 
clinical trials (Gray et al., 2016; Chege et al., 2017).  However, unlike the study conducted by 
Chege (2017) and Gray (2016) and their colleagues, the Env protein used in this study included 
intact V1/V2 loops.  This protein was administered in formulation with an alum-based adjuvant 
(Imject®, Thermo Scientific) 
The candidate SAAVI MVA-C vaccine was administered concurrently with HIV envelope 
protein, gp140, in order to elicit both HIV-specific cellular and humoral responses.   
2.2.2. Parasite 
A Puerto Rican strain of Schistosoma mansoni and used for infection of Biomphalaria glabrata 
snails.  These were kept in regulated light/dark cycle conditions with a constant temperature of 
25°C in 1x Lepple buffer (see appendix 1), and were fed commercial fish flakes daily.  
Infectious S. mansoni cercariae were obtained by exposing S. mansoni infected Biomphalaria 
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glabrata snails to direct light for 30 minutes.  Water containing the cercariae was harvested 
and the parasites were counted. 
2.2.3. Peptides and reagents 
Culture medium 
Splenocytes and peptides were diluted and stored in culture media prepared under sterile 
conditions in our laboratory.  To prepare 100 mL of the media, 1 mL of Penicillin-Streptomycin 
(Gibco, UK) and 10 mL heat-inactivated fetal bovine serum (FBS) (Thermo Scientific, South 
America) was added to 88.9 mL RPMI 1640 (1X) with GlutaMAX™ -I (Gibco by Life 
Technologies, UK).  Thereafter, 100 µL of 50 mM 2-Mercapto Ethanol (2ME) (Sigma-Aldrich) 
was added.  This complete culture medium mixture was termed R10 media. 
Peptides 
Peptides used in stimulation assays, as well as a negative and a positive control, all listed in 
table 2.1, were diluted in R10 complete media to final concentration of 2 µg/mL.   
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Table 2. 1 - Stimulant and control peptides used in experimental assays 
Stimulant/Control Description Peptide sequence Manufacturer 
ConA  Polyclonal stimulant 
Assay positive control 
 Sigma-Aldrich, USA 
Irrelevant peptide  
 
H-2Kd binding peptide 
Assay negative 
control; 
TYSTVASSL Bachem, Switzerland 
Gag CD8 Gag H-2d-restricted 
class I peptide (CD8 
peptide) 
AMQMLKDTI Bachem, Switzerland 
Gag CD4 (13 and 
17) 
Gag MHC class II-
restricted peptides 
(CD4 peptides) 
NPPIPVGRIYKRWIILGLNK 
and 
FRDYVDRFFKTLRAEQATQE 
Bachem, Switzerland 
RT CD8 RT H-2d-restricted 
class I peptide (CD8 
peptide) 
VYYDPSKDLIA Bachem, Switzerland 
RT CD4 RT MHC class II-
restricted peptide 
(CD4 peptide) 
KQWPLTEVKIKALTAI Bachem, Switzerland 
Env CD4 Env MHC class II-
restricted peptide 
(CD4 peptide) 
YGVPVWREAKTILFCA Bachem, Switzerland 
Env CD8 Env H-2d-restricted 
class I peptide (CD8 
peptide) 
RGPGRAFVTI Bachem, Switzerland 
SEA Soluble egg antigen; a 
crude extract of 
heterogenous proteins. 
 Theodor Bilharz 
Research Institute, 
Egypt 
 
2.2.4. Mice 
Groups of five or six, 6-8 week old, female BALB/c mice were acquired from the South African 
Vaccine Producers (SAVP, Johannesburg, South Africa) and were housed in individually 
ventilated cages under BSL2 conditions at all times within the RAF (Research Animal Facility) 
of the Health Science Faculty.  These BALB/c mice were chosen due to the well-known 
immune systems.  Several epitopes present in HIV-1 Gag, RT and Env have been shown to 
bind the H-2Kd MHC class 1 and class II molecules of BALB/c mice and able to activate 
corresponding CD8+ and CD4+ T cells respectively (Mata et al., 1998; Mata & Paterson, 1999; 
Casimiro et al., 2002). This made it possible to use synthetic peptides shown in Table 2.1 in T 
cell assays to evaluated HIV-specific CD4+ and CD8+ T cell responses in BALB/c mice. The 
epitope sequence RGPGRAFVTI from HIV-1 gp120 Env, a mouse H-2d-restricted class I 
peptide, was specifically included in the SAAVI MVA-C vaccine for evaluation of responses 
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to Env in BALB/c mice (Burgers et al., 2008).  The Gag peptide (AMQMLKETI) has been 
shown to bind to MHC class I molecules at the glutamine of P3 with pocket D of Kd, and thus, 
the MHC class I molecule H-2 Kd, present in BALB/c mice, is an important motif for the 
interaction of CTL epitopes with the gag peptide (Mata et al., 1998).  A later study identified 
epitopes present in the p24 portion of the gag protein in BALB/c mice and found that two of 
these epitopes are common to the H-2b and H-2d MHC class II molecules (Mata & Paterson, 
1999).  In addition, characterization of stimulatory peptides from pools of short overlapping 
peptides indicated that optimized RT gene constructs are able to effectively activate both pol-
specific CD4+ and CD8+ T cells in BALB/c mice (Casimiro et al., 2002).  These studies 
demonstrate that a BALB/c mouse is a suitable model for evaluating HIV vaccine responses. 
2.3 Methods 
2.3.1 Animal ethics 
All experiments were performed in accordance to guidelines by the Animal Research Ethics 
Committee of UCT.  Experimental protocols were detailed in the project proposal that was 
reviewed by the Department of Pathology Research Committee.  The animal experiments were 
approved by the Faculty of Health Sciences Animal Ethics Committee (AEC) and the study 
was assigned protocol number 014/026.  In addition, the experimental protocols were detailed 
in the project proposal that was reviewed by the Department of Pathology Research Committee. 
Mice were monitored for changes in appearance and behaviour once a day during the entire 
course of the experiment.  Each mouse was weighed once a week to monitor for weight loss 
greater than 5% of original weight as an indicator for waning health.  The maximum and 
minimum temperature of the room was monitored each day and the light intensity was 
measured once a week to keep conditions controlled for optimal welfare of the animals. 
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2.3.2. Animal procedures 
Animal restraint 
Mice were anaesthetised with a mixture of ketamine hydrochloride (120 mg/kg body weight) 
and xylazine (16 mg/kg body weight) before cercarial infections, vaccinations and euthanasia 
were carried out.  These anaesthetics were diluted with saline to a final concentration of 120 
mg/kg ketamine and 16 mg/kg xylazine per mouse.  Mice weight generally ranged between 18-
22 g.  The anaesthesia was administered intraperitoneally.   
Vaccine inoculum administration 
The SAAVI MVA-C vaccine inoculum stocks were mixed diluted with 1 mM Tris buffer (pH 
9.0) to a concentration of 107 pfu/mL and administered intramuscularly under anaesthesia.  
Injections of 50 µL of the inoculum were made by hypodermic needle and syringe into the 
tibialis muscle of each hind leg (total dosage of 106 pfu per mouse).  The gp140 (TV-1)(HIV-
1/Clade C) protein (Immune Technology) was diluted with PBS to a concentration of 100 
µg/mL and formulated with an equal volume of Imject® Alum adjuvant (Thermo Scientific, 
USA) and sterile PBS and administered intraperitoneally (total of 10 µg per mouse). 
Parasite infection 
For parasitic cercariae infections, the abdomens of the mice were shaved by hand and the mice 
were then sedated with ketamine/xylazine mixture at a dosage stated above.  The shaved areas 
were exposed to 30 cercariae in water for 20 minutes.  This infection model mimicked the 
natural route of infection.  
Experimental endpoint 
At experimental endpoints, mice were anaesthetised with ketamine/xylazine mixture (as 
detailed above) and blood was collected by cardiac puncture.  Mice were then euthanized by 
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cervical dislocation before the spleens and livers were harvested and stored in R10 media for 
transportation for weighing and processing in the laboratory. 
2.4. Experimental design 
The SAAVI MVA-C vaccine and Env gp140 protein were administered concurrently as 
previously described (see 2.2.1) at the start of the experiment to two groups of 5 or 8 mice.  
Fourteen days later, one group of vaccinated mice and one group of unvaccinated mice were 
infected with S. mansoni cercariae as previously described (see 2.3.2).  Eight weeks thereafter, 
the vaccinated mice were then boosted with SAAVI MVA-C and Env gp140 protein at the 
same dose as the initial priming vaccination.  The experimental endpoint was twelve days after 
the boost vaccination, and the mice were euthanised and samples were collected (see 2.3.2).  
This experiment was repeated three times at different dates to ensure reproducibility.  
Table 2. 2 - Experiment timeline: Infection model 
Group Day 0 
Prime Vaccination 
Day 14 
Cercariae infection 
Day 70 
Boost vaccination 
Day 82 
Euthanasia 
Vaccine 
(n=5) 
SAAVI MVA-C; i.m.  
Env gp140 with adjuvant; 
i.p. 
 SAAVI MVA-C; i.m. 
Env gp140 with adjuvant; 
i.p. 
Collect blood by cardiac 
puncture; harvest spleen 
and liver 
Vaccine+Sm 
(n=8) 
SAAVI MVA-C; i.m. 
Env gp140 with adjuvant; 
i.p. 
Infect with 30 live 
cercariae 
SAAVI MVA-C; i.m. 
Env gp140 with adjuvant; 
i.p. 
Collect blood by cardiac 
puncture; harvest spleen 
and liver 
Naive 
(n=5) 
   Collect blood by cardiac 
puncture; harvest spleen 
and liver 
Sm 
(n=8) 
 Infect with 30 live 
cercariae 
 Collect blood by cardiac 
puncture; harvest spleen 
and liver 
 
2.5.  Laboratory protocols 
2.5.1. Processing of samples 
Isolation of splenocytes 
After harvesting the spleens from each mouse, the spleens were pooled per group onto one 
sterile wire mesh cell strainer (pore size: 70 µm) (Sigma-Aldrich) in a sterile petri dish and 
mashed through with a 5 mL syringe plunger.  After washing the strainer with RPMI (Gibco 
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by Life Technologies, United Kingdom), the cell suspension was transferred into a sterile 
50 mL tube and washed by two centrifugation and resuspension steps.  Cells were counted for 
each group on a standard 0.1 mm deep hemocytometer (Marienfeld, Germany) using a 20 µL 
sample stained with Turks solution (Gentian violet and 1-2% acetic acid), which stains the 
nucleus of cells and hemolyses erythrocytes, and thus enables all nucleated cells to be counted.  
The viability of live cells was then assessed by staining a separate 20 µL sample with Trypan 
Blue to count dead cells in the sample.  Cells for CBA were removed (1.5 x 107 cells/mL, in 3 
mL).  The remaining cells were lysed with red blood cell (RBC) lysis buffer (Sigma-Aldrich, 
United Kingdom) and recounted.  Finally, the lysed cell solution was separated for ELISPOT 
assays (5 x 106 cells/mL, in 4 mL) and flow cytometry (1 x 107 cells/mL, in 1 mL) and aliquoted 
into their respective plates (100 µL/well).   
Separation of serum 
Blood samples were collected in serum microtainer tubes (BD Bioscience, USA) and stored at 
room temperature for 4-8 hours to allow clotting before centrifuging (2000 rpm for 10 minutes).  
Serum was collected and aliquoted into 10 tubes and stored in a -20°C freezer until use in 
ELISA assays.   
Preparation of livers for histology 
Harvested livers were collected in R10 media, weighed and subsequently transferred to 
paraformaldehyde solution (4% paraformaldehyde in PBS) in separate tissue containers.  These 
were then stored at room temperature until they were sent to a service provider (Department of 
Surgery, UCT) for sectioning and preparation of histological slides. 
2.5.2. Enzyme-linked immunospot (ELISPOT) assay 
The enzyme-linked immunospot (ELISPOT) assay was developed from traditional enzyme-
linked immunosorbent assay (ELISA) techniques in the early 1980s (Sedgwich & Holt, 1983).  
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It was initially an assay for detecting antibodies secreted from B cells and gradually evolved to 
a method for detecting cytokines or other soluble mediators secreted from various cell types.  
This assay allows the direct quantitative measurement of number of cytokine secreting cells at 
the single cell level.  The function of cells can be determined from the types of cytokines 
secreted by cells in response to different stimuli. The ELISPOT assay is viewed as robust, 
reliable, and reproducible immunological tool (Tanguay & Killion, 1994). 
We used ELISPOT assays to measure T cell-mediated immune responses by measuring the 
number of CD4+ and CD8+ T cells secreting the cytokine after being stimulated by an array 
of various antigens.  This type of assay utilizes the sandwich (ELISA) technique whereby a 
monoclonal or polyclonal capture antibody which is specific to the chosen cytokine is coated 
onto a polyvinylidene difluoride (PVDF) backed microtitre plate.  Stimulated cells are 
incubated in the wells and, during this incubation period, the immobilized antibody coated onto 
the plate binds the cytokine secreted by the cells.  A biotinylated polyclonal antibody, alkaline-
phosphatase conjugated to streptavidin is added which binds to the cytokine already bound to 
the capture antibody.  The streptavidin shows up the localization of the bound cytokine as spots 
after addition of a colour developer (such as NovaRed), whereby one spot generated represents 
one T cell producing the cytokine.  Thus, this assay can directly measure a T cell mediated 
immune response and thus the presence of the vaccine-induced immunity.  
In this study, we used the ELISPOT technique to measure IFN-γ- and IL-2-producing T cells. 
A BD Mouse IFN-γ ELISPOT kit and a BD Mouse IL-2 ELISPOT kit (both BD Bioscience, 
USA) were performed according to established laboratory protocols (Shephard et al., 2008).  
Peptides, as well as a negative and a positive control, all listed in table 2.1, were diluted in R10 
complete medium (to final concentration of 2 µg/mL) before incubating with 500 000 
splenocytes per well.  This was conducted in triplicate wells for each group of mice.  The 
reaction was stopped after 22-24 hours incubation at 37°C with 5% CO2.  Nova Red substrate 
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(Vector Laboratories, USA) was used to develop the spots, according to manufacturer’s 
instructions, and thereafter the plates were analysed using the CTL ImmunoSpot system 
(Cellular Technology LTD, USA).  
After the plates were analysed using the CTL ImmunoSpot system (Cellular Technology LTD, 
USA), the spots on the images were visually inspected to determine if debris spots were 
counted by the CTL reader’s software.  If such debris spots are identified, these are deleted 
manually on the software.  Thereafter, the mean number of spots per group per peptide as well 
as the standard deviation were calculated.  The background was removed (double the negative 
control, maximum negative control value of 15 spots or sfu < 30) and the remaining positive 
results were expressed as spot forming units per million splenocytes (sfu/106).  
2.5.3. Intracellular cytokine staining (ICS) 
Intracellular cytokine staining (ICS) is the process of staining for intracellular markers such as 
cytokines, and for surface markers that determine the cell phenotype. The staining uses 
antibodies that are conjugated to a fluorochrome which make it possible for detection by a flow 
cytometer.  Fluorescence-activated cell-sorting (FACS) flow cytometry enables one to measure 
and analyse the characteristics of a single particle as it moves through a laser.  The laser light 
excites the fluorochrome which generates different light signals that are collected via a system 
of optics and filters for detection which allows for measurement of the particle’s size, 
granularity and fluorescence.     
The flow cytometer utilizes a pressurised fluidic system to allow cells to be taken up through 
the flow cell.  The cells pass the laser individually and the antibody-conjugated fluorochromes 
that are bound to a cell become excited by the laser and emit light at particular wavelengths, 
which are then directed by the optics of the flow cytometer to detectors. These wavelengths are 
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measured by the photomultiplier tubes.  These detectors convert the optical signals into digital 
data, ready to be analysed by the FlowJo® program (Tree Star Inc., USA). 
Cytokines, IFN-γ, TNF-α and IL-2, as well as the proportionality of activated CD8+ and CD4+ 
T cells was measured by ICS to identify the memory and function phenotypes of T cell subsets 
recognising the vaccine/parasite peptides.  The production of these Th1 cytokines due to 
peptide stimulation of splenocytes was measured by ICS and flow cytometry. 
Splenocytes were diluted to 1 million cells/well in R10 media and stimulated with peptides 
(Table 2.1), with a negative control of unstimulated splenocytes was also included for each 
group.  The plates were incubated at 37°C for 2 hours before brefeldin-A (BFA; Sigma-Aldrich, 
USA) was added to each well (4 µg/well, 20 µg/mL), and incubated for a further 4 hours.  Cells 
were washed with PBS and stained with ViViD (0.05 µg/well) (Invitrogen, USA) for 20 
minutes at room temperature in darkness.  The cells were then washed again with PBS and 
blocked with 50 µL blocking solution (0.12 µL normal mouse serum, 0.12 µL normal rat serum, 
0.16 µg CD16/32 (BD Biosciences, USA)) at 4° for 15 minutes.  Cells were then incubated at 
4°C for 20 minutes in a final volume of 100 µL stain buffer (BD Biosciences, USA) containing 
0.05 µg of each of the following fluorochrome-conjugated surface antibodies: CD3 - Alexa 
700, CD4 - PE Cy-7, CD8 - APC-Cy7, CD44 – FITC and CD62L - APC. After incubation, 
unbound antibodies were removed from solution using a wash step before fixation by 
incubation at 4°C for 30 minutes with fixation/permeabilization buffer (BD Biosciences, USA).  
Fluorochrome-conjugated cytokine antibodies were diluted in wash buffer (BD Biosciences, 
USA) and 100 µL (0.2 µg TNF - PE, 0.06 µg IFN-γ - PE and 0.06 µg IL-2 - PE) was added to 
each tube before incubating at 4°C for 20 minutes.  After washing twice, cells were resuspended 
in CellFix (BD Biosciences, USA.  Acquisition was then conducted on a BD LSRII (BD 
Biosciences, USA), and data was analysed using FlowJo V10.  The gating strategy is illustrated 
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below (Figure 2.1).  Cytokine positive (PE+) cells were undetectable and this was therefore 
excluded from the gating strategy. 
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Figure 2.1 - Gating strategy used for flow cytometry analysis of vaccine peptide-specific activated CD4+ 
and CD8+ cells.  Time gate, lymphocytes, singlets, live CD3 cells, which subsequently bifurcates activated CD4 
cells and activated CD8 cells and, finally, CD4 T memory cells (Tcm and Tem) gated on activated cells and CD8 
T memory cells (Tcm and Tem) gated on activated cells.  Splenocytes were stimulated with PMA (positive 
control), Gag, Pol, Env (CD4), Env (CD8), SEA or R10 media only (unstimulated).  Time gates (1) were plotted 
for each laser. Lymphocytes (2) were gated based on the relative size and granularity of the cells and plotted as 
forward scatter area (FSC-A) versus side scatter area (SSC-A).  Singlet gates (3) based on forward scatter height 
(FSC-H) and forward scatter area (FSC-A) were used to exclude doublet cells.  Live CD3+ cells (4) were gated 
on ViViD negative populations and CD3 positive populations.  The activation of live CD4+/CD8+ lymphocytes 
(5a/b) was then determined by the CD4+/CD8+ population positive for CD44. The memory phenotype of activated 
CD4+/CD8+ T cells (6a/b) was then delineated by the CD62L marker as central memory (CD44+CD62L+) and 
effector memory (CD44+CD62L−) T cell populations.  
1 2 3 
4 
5a 5b 
6a 6b 
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The number of activated CD44+ T cells was calculated based on the percentage data collected 
from FlowJo®, worked out per 100 000 cells (the number of events counted).  This was then 
applied to the number of splenocytes counted per spleen. After the spleens were pooled, the 
concentration of splenocytes per ml were counted and extrapolated to total number of 
splenocytes.  This could then be divided by the original number of spleens pooled per group.  
Positive responses were those above a cut-off value of 0.05% CD44-expressing T cells. 
2.5.4. Cytometric bead array (CBA) 
The cytometric bead array (CBA) (BD Bioscience, South Africa) was used to quantify the 
concentrations of particular extracellular antigen-specific cytokines in a sample using flow 
cytometry to determine if bias toward a Th1 or Th2 cytokine response was occurring.  This 
assay utilizes flow cytometry as an analytical tool that allows for the discrimination of different 
particles on the basis of size and fluorescence. The CBA kit uses a variety of beads with discrete 
fluorescence intensities that have been coated with capture antibodies specific for particular 
cytokines and their proteins in order to detect multiple cytokines from a single sample.  The 
“capture beads” are mixed with the phycoerythrin (PE)-conjugated detection antibodies and 
incubated with recombinant protein standards as well as test samples.  This will form 
“sandwich” complexes that can then be analysed by a flow cytometer. 
Processed splenocytes (as described in 3.4.1) were pooled per group and stimulated with 
peptides, as listed in table 2.1, in a 96 well round-bottomed plate.  This was done in duplicate 
for each group of mice.  The plate was incubated at 37°C with 5% CO2 for 48 hours, thereafter 
the supernatants were harvested without disturbing the cell pelleted at the bottom of the wells.  
The supernatants were then stored at -20°C until the CBA was commenced, and then the 
duplicates were pooled together for the assay.  The CBA Mouse Th1/Th2/Th17 cytokine kit 
(BD Bioscience, USA) measures Th1 cytokine (IFN-γ, TNF-α, IL-2), Th2 cytokine (Il-4 and 
IL-6) and regulatory cytokine (IL-10) levels and was conducted according to the 
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manufacturer’s instructions.  Data was acquired using a BD LSRII (BD Bioscience, USA) and 
analysed by FCAP Array Software (Soft Flow Inc., Hungary).    
The FCAP Array software located clusters of fluorescence (to which analytes have been 
assigned) and then determined the median fluorescence intensity (MFI) of the detector antibody 
for each analyte.  Cytokine standards (provided in the kit and prepared as per manufacturer’s 
instructions (BD Science, South Africa)) were serially diluted and the MFI of these standards 
enabled the software to calculate a curve from which the concentrations for each of the 
measured analytes in the samples are calculated.  The results were calculated as picogram of 
cytokine per mL (pg/mL) using the standard curve extrapolated from the set of standards.  
Finally, the results from the stimulation of the splenocytes with the irrelevant peptide were 
used as the cut off for positive responses.  Any reading above 2x the average of the results for 
the irrelevant peptide stimulation and were deemed positive.  This was further confirmed if the 
results were higher than the theoretical limits of detection were 0.1 pg/mL for IL-2, 0.03 pg/mL 
for IL-4, 1.4 pg/mL for IL-6, 0.5 pg/mL for IFN-γ, 0.9 pg/mL for TNF, 0.8 pg/mL for IL-17A, 
and 16.8 pg/mL for IL-10 (Wei et al., 2014, BD Bioscience CBA Mouse Th1/Th2/Th17 
cytokine kit manual). 
2.5.5. Enzyme-linked immunosorbent assay (ELISA) 
Enzyme-linked immunosorbent assays (ELISA), are routinely used to measure the 
concentration of peptides, antibodies, cytokines and antigens in a solution.  An enzyme is 
covalently bonded to a specific monoclonal/polyclonal antibody that recognises and binds to 
an antigen target.  The antibody-enzyme complex that forms will catalyse a colour-changing 
reaction.  Therefore, the amount of colour change that occurs is directly proportional to the 
presence of antigen.  The indirect ELISA that was employed here allows for both the detection 
and comparable quantification, whereby antigen protein is coated onto wells of a plate, and 
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antibodies in the sample are allowed to bind.  The enzyme-linked detection antibodies bind to 
the bound sample antibodies and, when substrate is added, the colour-changing reaction occurs. 
Immunoglobulin (Ig) production in response to Env gp140 was quantified by ELISAs 
conducted on serum collected from each mouse.  Maxisorp™ 96-well plates (Nunc, USA) were 
coated with 0.5 µg/mL (50 ng/well) of TV-1 HIV-1C Env gp140 protein (Immune 
Technologies) and incubated at 4°C overnight.  Serum was diluted to 1:5000 in 2.5% skimmed 
milk (2.5g dehydrated milk in 100 mL PBS) and added to duplicate wells.  Aliquots of pooled 
sera from gp140 Env-immunized mice (which had high OD values) were used as a standard to 
generate a standard curve.  Thereafter, antibody unit values, starting with a maximum value of 
1000, were allocated to the OD values of the serially diluted standard serum and used to 
enumerate the curve. To determine the antibody values of the test samples, antibody values 
were extrapolated from the standard curve using the test sample OD values.  
 The standard sample was serially diluted two-fold, twelve times, starting at a dilution of 1:200 
in 2.5% skimmed milk.  This was also done in duplicate.  The serum aliquots collected from 
naïve mice were pooled and included as a negative control at a dilution of 1:5000 in 2.5% 
skimmed milk, this was done in triplicate.  Once the test and control sera were aliquoted, the 
plate was once again incubated at 4°C overnight to increase time for binding.  Serum IgG, 
IgG1, IgG2a and IgG2b were detected using anti-IgG/IgG1/IgG2a/IgG2b conjugated to horse 
radish peroxidase (HRP) (Southern Biotech, USA) diluted to 1:1000 in 5% skimmed milk (5g 
dehydrated milk in 100 mL PBS) and developed using tetramethyl-benzidine (TMB; KPL, 
Gaithersburg, MD).  The absorbance was measured on a VersaMax microplate reader 
(Molecular Devices Corporation, Sunnyvale, CA)) at 450 nm with a reference filter at 540 nm.  
The OD values from the reference filter were subtracted to give net OD values.  The net OD 
from the standard serum dilutions were assigned antibody units and used to generate a standard 
curve. To generate the antibody units for the test samples, their net OD values were 
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extrapolated from the standard curve.  The triplicate negative controls were averaged, and the 
average net OD values plus 2 standard deviations was defined as the cut-off value.  Any test 
sample OD value that was less than the cut-off value was assigned a zero antibody unit.  The 
final results are reported as gp140 Env antibody units.   
Another set of ELISA experiments were performed to evaluate the total immunoglobulin levels 
(non-specific antibody immune responses) in the mouse sera in order to elucidate the Th1/Th2 
bias of the different mouse groups.  Thus, to quantify total IgG1, IgG2a and IgG2b levels in 
mouse sera, Maxisorp™ 96-well plates (Nunc, USA) were coated with 1 µg/mL (0.1 µg/well) 
goat anti-mouse Ig capture antibody (Southern Biotech, USA) and incubated at 4°C overnight.  
Sera from test mice were diluted to 1:5000 in 2.5% skimmed milk and added to duplicate wells.  
The standards provided were diluted to 1 µg/mL and then serially diluted two-fold, twelve 
times across the plate.  This was also done in duplicate on every plate.  Once diluted sera were 
aliquoted, the plate was once again incubated at 4°C overnight to increase time for binding.  
The levels of IgG, IgG1, IgG2a and IgG2b in the sera were detected using anti-
IgG/IgG1/IgG2a/IgG2b conjugated to horse radish peroxidase (HRP) (Southern Biotech, USA) 
diluted to 1:1000 in 5% skimmed milk and developed using tetramethyl-benzidine (TMB; 
Abcam, USA).  The absorbance was measured using the VersaMax microplate reader as 
described above.  Two blank wells (incubated with 100 µL 2.5% skimmed milk without sera) 
were included as negative controls.  The average OD value of these negative controls plus 2 
standard deviations was used as the negative cut off for this assay.  Any test sample OD value 
that was less than the cut-off value was assigned a zero antibody unit 
2.5.6. Histology 
Chronic schistosomiasis has shown to be a consequence of granuloma formations in tissue.  
The eggs of S. mansoni are carried in the circulatory system into the liver, principally, and the 
eggs become lodged within the tissue.  The CD4+ T lymphocyte response induced by the egg 
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antigens further promotes the formation of granulomatous lesions around each of the helminth 
eggs in the tissues.  These granulomas are comprised of collagen fibres, macrophages, 
eosinophils and the aforementioned CD4+ T cells.  As the eggs die within the tissues, the 
surrounding granulomas are replaced by fibrous plaques.  As such, confirmation and the degree 
of chronic infection can be measured by the presence and multitude of granulomas as well as 
the extent of hepatic fibrosis (Pearce & MacDonald, 2002).  In this experiment, observation of 
granulomas in the liver were used to confirm chronic infection. 
Liver tissue samples were stored in 4% formaldehyde solution (diluted in PBS) and sent to the 
Department of Surgery (UCT) for preparation of histological slides (i.e. embedded the samples 
in paraffin and cut to 5-7 µm sections and stained with haematoxylin and eosin (H&E)).  These 
slides were examined under a light microscope (Nikon 90i Automated compound microscope 
with a camera (DCT DS-SMc)) and micrographs of liver granuloma were captured using a 
Nikon 5.0 mega pixel colour digital camera (DCT DS-SMc).   
2.6. Data analysis and statistics 
In order to accurately assess the effect of schistosomiasis on the immunogenicity of the 
candidate HIV vaccine to boost cellular and humoral immune responses, statistical analyses 
were conducted to compare across the groups (experimental and control groups).  Responses 
to vaccine peptides were compared between the vaccinated groups that were either infected or 
uninfected.  The responses to SEA were compared between infected mouse groups that were 
vaccinated or unvaccinated.  Results were analysed in Prism® (GraphPad Software, USA), 
using two-tailed Student t-tests or Mann–Whitney–Wilcoxon tests for significance.  Statistical 
p values < 0.05 were considered to be significant. 
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3. Results 
3.1. Introduction 
Our aim was to investigate whether an ongoing chronic helminthiasis attenuates the capacity 
of candidate HIV vaccine (SAAVI MVA and a subunit HIV envelope protein) to mount booster 
responses in a mouse model.  As such, we analysed the cell-mediated and humoral responses 
for mice infected with S. mansoni (Sm), vaccinated with SAAVI MVA-gp140 (Vaccine), naïve 
or both vaccinated and infected (Vaccine + Sm).  The physical differences in the livers and 
spleens between these groups was also investigated by histology and cell counts.  
It was determined previously that peak responses would be elucidated twelve days after MVA-
gp140 boost inoculation (Shephard et al., 2008; Chapman et al., 2013; Jongwe et al., 2016). 
As such, mice were euthanised at this time point and the spleens were pooled within each 
group.  
3.2. Cell-mediated Responses 
3.2.1. Magnitude of IFN-γ-producing T cell responses to vaccine peptides by ELISPOT 
assay 
An IFN-γ ELISPOT assay was used to quantify the T cells secreting IFN-γ in response to 
vaccine peptides.  Results from the positive control (ConA) and the negative control (the 
irrelevant peptide) are not shown (Figure 3.1).  The unvaccinated mouse groups did not elicit 
any responses above the background responses, with regards to vaccine peptides in this assay.   
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Figure 3.1 - Quantification of T cells secreting IFN-γ in response to vaccine peptides. Cumulative (A) and 
individual (B) IFN-γ ELISPOT CD4+ and CD8+ responses of Vaccine mice compared to Vaccine+Sm mice. This 
assay was conducted twelve days after SAAVI MVA-gp140 boost, on pooled splenocytes stimulated with six 
different vaccine peptides. Bars represent the magnitude of net responses to individual peptides, expressed as spot 
forming units (sfu) per million splenocytes after removing background responses, with SEM shown. (*p < 0.05 
**p=0.0087).  Exemplar wells for the Vaccine+Sm group are also shown (C). 
 
C 
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The Vaccine mouse group elicited the higher IFN-γ responses (1733 sfu/106) than Vaccine+Sm 
group (948 sfu/106).  Infection with helminths was shown to significantly decrease the number 
of T cells responding with IFN-γ to vaccine peptides (p<0.01).  And, while all peptides elicited 
high IFN-γ-production responses in the Vaccine group, the highest responses were produced 
in response to the RT (CD8) peptide (734 ± 221 sfu/106).  This RT (CD8) peptide also elicited 
the highest responses in the Vaccine+Sm mouse group of all the other peptides (521 ± 
116 sfu/106). 
Responses to each peptide were decreased, no peptide was able to maintain the same responses 
as the Vaccine group.  Nevertheless, statistically significant differences in IFN-γ producing T 
cells were only observed for the RT (CD4) (Vaccine; 124 ± 7 sfu/106, Vaccine+Sm; 43 ± 
27 sfu/106) and Env (CD8) (Vaccine; 467 ± 73 sfu/106, Vaccine+Sm; 241 ± 31 sfu/106) 
peptides (*p < 0.05).  
The Vaccine group elicited an average of 1333 and 400 net IFN-γ sfu/106 splenocytes to CD8+ 
and CD4+ peptides respectively.  These results were 1.6 and 3.1 fold higher, respectively, than 
Vaccine+Sm group, but this was not statistically significant.   
3.2.2. Magnitude of IL-2-producing T cell responses to vaccine peptides by ELISPOT 
assay 
An IL-2 ELISPOT assay was used to quantify the T cells secreting IL-2 in response to vaccine 
peptides.  Results from the positive control (ConA) and the negative control (the irrelevant 
peptide) are not shown (Figure 3.2).  The unvaccinated mouse groups did not elicit any 
responses above the background responses, with regards to vaccine peptides in this assay.   
Chapter 3 – Results 
56 
 
Va
cc
ine
Va
cc
ine
 + 
Sm Sm
Na
ive
 
0
100
200
300
N
et
 IL
-2
 s
fu
/1
06
 s
pl
en
oc
yt
es
Gag (CD8)
Gag (CD4)
RT (CD8)
RT (CD4)
Env (CD8)
Env (CD4)
Ga
g (
CD
8)
Ga
g (
CD
4)
RT
 (C
D8
)
RT
 (C
D4
)
En
v (
CD
8)
En
v (
CD
4)
0
50
100
150
200
250
Peptide
Ne
t I
L-
2 
sf
u/
10
6  s
pl
en
oc
yt
es Vaccine
Vaccine + Sm
*
B
A
 
Figure 3.2 - Quantification of T cells secreting IL-2 in response to vaccine peptides. Cumulative (A) and 
individual (B) IL-2 ELISPOT CD4+ and CD8+ responses of Vaccine mice compared to Vaccine+Sm mice. This 
assay was conducted twelve days after SAAVI MVA-gp140 boost, on pooled splenocytes stimulated with six 
different vaccine peptides. Bars represent the magnitude of net responses to individual peptides, expressed as spot 
forming units (sfu) per million splenocytes after removing background responses, with SEM shown. (*p < 0.05).  
Exemplar wells for the Vaccine+Sm group are also shown (C). 
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The Env (CD4) peptide elicited the greatest IL-2-producing T cell responses in both vaccinated 
mouse groups (Vaccine; 150 ± 52 sfu/106, Vaccine+Sm; 41 ± 15 sfu/106) however, the levels 
were not statistically significant between the groups.  Responses by way of IL-2-producing 
cells were highest in the Vaccine group (195 sfu/106), with the Vaccine+Sm group having 
slightly supressed responses (64 sfu/106), but not significantly.  Two peptides failed to elicit 
IL-2-producing T cell responses above the background: Gag (CD8) and Env (CD8).  Again, 
responses to each vaccine peptide were decreased in the Vaccine+Sm group and no peptide 
was able to produce the same responses as the Vaccine group.  But, only one peptide, RT 
(CD4), elicited significantly lower IL-2 producing T cells in the Vaccine+Sm group (9 ± 6 
sfu/106) when compared to the Vaccine group (37 ± 5 sfu/106) (*p < 0.05).  Overall, the Vaccine 
group produced 3.4 fold greater net CD4+ IL-2 sfu/106 splenocytes than Vaccine+Sm group 
(p=0.045).     
3.2.3. Magnitude of IFN-γ and IL-2 T cell responses to helminth egg antigens 
To determine the effect of vaccination on the magnitude of T cell responses to helminth antigen, 
SEA was used to stimulate splenocytes from all mouse groups in the IFN-γ ELISPOT as well 
as the IL-2 ELISPOT assays, in exactly the same concentration as the other peptides used in 
the assay.  As expected, uninfected groups did not elicit T cell responses to the SEA peptide. 
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Figure 3.3 - Quantification of T cells secreting cytokine in response to SEA. IFN-γ ELISPOT (A) and IL-2 
ELISPOT (B) T cell responses of Sm mice compared to Vaccine+Sm mice.  This assay was conducted twelve 
days after MVA-gp140 boost, on pooled splenocytes stimulated with the SEA peptide. Bars represent the 
magnitude of net responses expressed as spot forming units (sfu) per million splenocytes after removing 
background responses.  Exemplar wells for the Vaccine+Sm group are also shown (C). 
 
The Sm group showed higher IFN-γ T cell responses (343 ± 54 sfu/106) than the Vaccine+Sm 
group (199 ± 55 sfu/106).  This was also the case for IL-2-producing T cells, between the Sm 
group (97 ± 28 sfu/106) and the Vaccine+Sm group (58 ± 12 sfu/106).  However, no significant 
differences exist between these mouse groups.  Thus, both infected groups had similar recall 
immune responses to the helminth egg antigen.  
C 
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3.2.4. Quantification of secreted cytokines in response to vaccine peptides 
Ex vivo secretion of Th1 cytokines (IFN-γ, TNF-α and IL-2) as well as Th2 cytokines (IL-4 
and IL-6) and regulatory cytokine (IL-10) by the mouse splenocytes were quantified by a 
cytometric bead array using a mouse CBA Th1/Th2/Th17 kit as described in the Methods 
section (2.5.4.).  The production of these cytokines was measured following 48 hour 
stimulation in culture with one of the vaccine peptides (table 2.1) or SEA.  
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The cumulative concentrations of various cytokines vary widely, with IFN-γ and IL-6 having 
the highest concentrations. However, TNF-α, IL-4, IL-10 and IL-2 had comparatively low 
concentrations in all samples. Cytokine responses were consistently present specific to 
Figure 3.4 - Cytokine secretion from mouse splenocytes to CD8+ and CD4+ vaccine peptides.  A cytometric 
bead array was used to quantify the secretion of Th1 (A: IFN-γ, TNF-α and IL-2), Th2 (B: IL-6 and IL-4) and 
regulatory (C: IL-10) cytokines 12 days after SAAVI MVA-gp140 boost.  Bars represent concentration of 
cytokines secreted in response to vaccine peptides, expressed as pictograms per millilitre (pg/mL) after removing 
background responses (p < 0.05). 
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RT (CD4) peptide, with TNF-α responses in the Vaccine+Sm group being the only exception.  
In fact, this group elicited no TNF-α above detection levels.   
As shown in Figure 3.4A, production of the Th1 and Th2 cytokines as well as IL-10 was 
suppressed in the Vaccine+Sm group, when compared to the Vaccine group.  All the Th1 
cytokines, IFN-γ, TNF-α, and IL-2, by splenocytes from Vaccine+Sm mice were generally 
decreased (IFN-γ; 585.587 pg/mL, TNF-α; 0 pg/mL, IL-2; 6.457 pg/mL) when compared to 
Vaccine mice (IFN-γ; 1165.56 pg/mL, TNF-α; 12.46 pg/mL   IL-2; 34.663 pg/mL).  Secretion 
of TNF-α was below detection levels for the Vaccine+Sm mouse group, and this was the only 
Th1 cytokine with statistical significance, whereby this Vaccine+Sm group secreted 
significantly lower levels of TNF-α than the Vaccine mouse group (p = 0.048).  For individual 
peptides, the only statistical significance that appeared between the two mouse groups was the 
secretion of IL-2 in response to Env (CD4), whereby IL-2 was significantly lower in the 
Vaccine+Sm group (2.477 ± 2.477 pg/mL) when compared to the Vaccine group (22.927 ± 
5.451 pg/mL) (p = 0.0269). 
With regards to the Th2 cytokines, IL-6 was secreted significantly more in response to vaccine 
peptides by the splenocytes of the Vaccine mice (369.757 pg/mL) when compared to the 
Vaccine+Sm mice (0 pg/mL) (*p=0.012).  The background for IL-6 secretion in Sm mice, as 
determined from the IL-6 responses to the irrelevant peptide, was notably high and many 
peptides could not exceed this.  The other Th2 cytokine detected, IL-4, was also secreted to 
significantly higher levels to vaccine peptides by the splenocytes of the Vaccine mice (12.653 
pg/mL) when compared to the Vaccine+Sm mice (0.37 pg/mL), however both of these 
concentrations are generally low (*p=0.031).  
The regulatory cytokine, IL-10, did not show any definitive difference between the two mouse 
groups.  Only two of the vaccine peptides elicited secretion of IL-10; RT (CD4) and Env (CD4).  
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The IL-10 production in response to RT (CD4) was generally reduced in Vaccine+Sm mice 
(vaccine; 11.367 ± 11.367 pg/mL, vaccine + Sm; 0 pg/mL).  This trend was also seen with IL-
10 secretion in response to Env (CD4) (vaccine; 7.257 ± 7.257 pg/mL, vaccine + Sm; 0.737 ± 
0.737 pg/mL). 
3.2.5.  Quantification of cytokines produced in response to SEA 
The analysis of the production of cytokines in response to the parasitic infection was also 
conducted using the cytometric bead array.  This assay was conducted using the supernatants 
of splenocytes from each group stimulated with SEA in the same conditions and concentrations 
as those used to analyse the vaccine peptides.  The groups that were not infected did not respond 
to the SEA stimulation and thus did not yield any results above the background in this regard.  
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Figure 3.5 - Cytokine secretion from mouse splenocytes to helminth egg antigen.  A cytometric bead array 
was used to quantify the secretion of Th1 (A: TNF-α and IL-2), Th2 (B: IL-6 and IL-4) and regulatory (C: IL-10) 
cytokines 12 days after SAAVI MVA-gp140 boost.  Bars represent concentration of cytokines secreted in response 
to SEA peptide, expressed as pictograms per millilitre (pg/mL) after removing background responses. 
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The Vaccine+Sm mouse group showed generally increased concentrations of both Th1 
cytokine, IL-2 in response to SEA (0.653 ± 0.653 pg/mL) when compared to the Sm group 
(0.44 ± 0.44 pg/mL).  However, this is incredibly low and not statistically significant.  The 
secretion of TNF-α in response to SEA was generally, but not significantly, higher in the Sm 
mouse group (13.07 ± 13.07 pg/mL) as opposed to the levels observed in Vaccine+Sm mice (0 
pg/mL).  The levels of IFN-γ secreted in response to SEA was not within detectable limits. 
It was observed that the Sm group had slightly more elevated IL-6 levels (642.6 ± 300 pg/mL) 
than the Vaccine+Sm mouse group (632.6 ± 61.57 pg/mL).  Similarly, for IL-4, the Sm mouse 
group had marginally higher levels in response to SEA (1.267 ± 1.267 pg/mL) when compared 
to the Vaccine+Sm group (0.986 ± 0.986 pg/mL).  However, both of these Th2 did not show 
significance differences between the two infected mouse groups.   
Levels of IL-10 were some of the highest to SEA.  The Sm mouse group had the higher IL-10 
levels (248.8 ± 51.14 pg/mL) than the Vaccine+Sm group (210.2 ± 51.14 pg/mL).  But again, 
there was no statistical difference in IL-10 concentrations between these infected mouse 
groups. 
3.2.6. Th1/Th2 bias in cytokine secretion 
The bias of the immunity to Th1/Th2-type was evaluated by the ratio of IFN-γ to IL-6 in 
response to stimulation with the ConA peptide.  As this was the positive control, all mouse 
groups elicited cytokine responses and the T helper type bias could be observed for each mouse 
group.  
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Figure 3.6 - IFN-γ/IL-6 ratio in response to ConA positive control peptide.  A cytometric bead array was used 
to quantify the secretion of Th1 cytokine, IFN-γ and Th2 cytokine, IL-6, 12 days after SAAVI MVA-gp140 boost, 
after removing background responses. 
 
The highest IFN-γ/IL6 ratio was observed in the naïve mouse group (32.07), showing the 
greatest Th1 bias.  The Vaccine group had the second highest apparent Th1 bias (16.837), 
almost half the naïve group.  The Sm mouse group had a ratio less than one (0.2), showing a 
greater secretion of IL-6 to ConA as opposed to IFN-γ secretion, and thus a strong Th2 bias.  
While slightly higher, the Vaccine+Sm mouse group showed a low ratio (1.607) when 
compared to the uninfected mouse groups. 
3.2.7. Distribution of activated T cell memory responses 
3.2.7.1 Activated T cells 
Flow cytometry analysis was used to quantify the vaccine specific cytokine responses induced 
by the MVA gp140 vaccine.  Unstimulated cells were included as a negative control, and this 
was controlled at 0.1% CD4+/CD8+ cells producing IFN-ߛ, TNF-α and IL-2 cytokines to 
confirm correct gating.  The unvaccinated mouse groups elicited no cytokine responses to the 
vaccine peptides tested, as expected.  However, no cytokine positive cells were detected for the 
other groups above this cut-off value using this gating strategy.   
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We then modified the gating strategy to determine the number of activated CD8+ and CD4+ 
T lymphocytes and the distribution of memory phenotypes for each group.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 - Representative dot plot graphs showing HIV-1 peptide (Env, Pol) activated CD4+ and CD8+ T 
cells in Vaccine, Vaccine+Sm, Sm and Naïve groups. Splenocytes were stimulated with HIV peptides (Pol and 
Env) for 6hrs at 37°C, 5% CO2. Staining of surface markers and ICS were performed using established protocol. 
The expression of CD44 (activation marker) were determined for CD4+ (left panel) and CD8+ (right panel) T 
cells gated on live CD3.  
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The accumulated activated CD8+ T cell populations elicited by the Vaccine mice were 
significantly greater than the naïve group (p < 0.01).  The Vaccine+Sm group was significantly 
greater than the Sm (p < 0.05) and the naïve (p <0.01) groups.  However, the Vaccine group 
and the Vaccine+Sm groups did not differ with any statistical significance.  Again, with the 
percentage of activated CD8+ T cells within the live CD3+ population, the Vaccine+Sm group 
roused a higher proportion of activated CD8+ T lymphocytes than the other three groups, but 
not with any significance.   
However, the CD4+ T cell activation profiles did show a significant difference between the 
Vaccine and the Vaccine+Sm mouse groups (p < 0.05).  The CD4+ T cells were more activated 
Figure 3.8 - Activated T cell responses to vaccine peptides. Vaccinated mouse T cell responses to vaccine 
peptides with or without infection. Magnitude of activated CD8+ and CD4+ T cells 12 days after SAAVI MVA-
gp140 boost.  Bars represent A) number of activated T cells per mouse spleen, and B) percent of activated T cells 
of live CD3+ cells.  Representative averages and standard deviation of three independent experiments. (**p <0.01; 
*p < 0.05) 
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in Vaccine+Sm mice when compared to those of the Vaccine mice.  The naïve mouse group 
elicited significantly lower responses than the other three groups (p < 0.05).  The percentage 
of activated CD4+ T cells within the live CD3+ population showed no significant differences 
amongst the groups, however, unlike that of the activated CD8+ T cells, the Sm group had the 
higher percentage of activated T cells per peptide. 
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3.2.7.2. Memory phenotype of activated T cells 
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Figure 3.9 – Comparison of memory distribution profiles of activated T cells between Vaccine+Sm and 
Vaccine groups. The frequencies of effector (Tem) and central (Tcm) memory of A) activated CD4+ and B) 
activated CD8+ populations after stimulation of splenocytes 12 days after SAAVI MVA-gp140 boost.   
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The CD8+ T cell memory distribution did not differ greatly between the two mouse groups. 
The greatest difference between the groups was seen for the Gag peptide, whereby a greater 
central memory profile was seen for the Vaccine+Sm group (59.37 ± 14.10%) when compared 
to the Vaccine group (51.156 ± 14.53%).  The effector memory profiled at averages between 
38% and 43.5% for all the peptides in the Vaccine+Sm, and between 42% and 48.8% for the 
Vaccine group.  The effector memory profile was much larger for globally activated CD4+ 
T cells, ranging from 65.6% (Env (CD8)) to 66% (Pol) for the Vaccine group, and 70.7% 
(Env (CD4)) to 73% (Pol) for the Vaccine+Sm group.  The central memory phenotype for 
activated CD4 T cells was decreased in Vaccine+Sm mice (Gag; 28.09 ± 3.95%, Pol; 26.45 ± 
4.66%, Env (CD4); 28.79 ± 6.95%, Env (CD8); 28.65 ± 3.29%) as opposed to the Vaccine 
group (Gag; 34.28 ± 8.35%, Pol; 33.53 ± 6.34%, Env(CD4); 33.92 ± 3.87%, Env (CD8); 38.76 
± 10.52%).  Thus, a greater proportion of effector memory CD4+ T cells were observed in the 
Vaccine+Sm mouse group.  
3.3. Humoral Responses 
3.3.1. HIV Env protein-specific antibody responses 
Env gp140-specific immunoglobulin responses were determined by IgG, IgG1, IgG2a and 
IgG2b ELISAs.  A sample with the highest was OD reading was assigned as the standard and 
was included on all plates that were run.  A plate blank was also included as well as a negative 
control serum from one of the mice in the naïve group and one of the mice from the Sm group. 
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The Vaccine mice presented with lower levels of IgG (Figure 3.10A) in the sera (145.1 ± 6.97 
AU) than in the sera of the mice that were Vaccine+Sm (162.2 ± 18.53 AU) but this was not a 
significant difference.  However, IgG1 levels to gp140 were significantly different between the 
Vaccine mice (21.6 ± 2.71 AU) and the Vaccine+Sm mice (43.17 ± 3.45 AU) (p < 0.0001).   
Figure 3.10 - Antibody responses to gp140.  Serum of individual mice was run to demonstrate IgG (A), IgG1 
(B), IgG2a (C) and IgG2b (D) responses to HIV Env gp140 protein subunit from the vaccination.  Serum from 
each mouse was collected by cardiac puncture 12 days after SAAVI MVA-gp140 boost.  Bars represent the 
average comparable concentrations of Ig for each group in gp140 Env antibody units (AU). (**** p < 0.0001; *** 
p < 0.001) 
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The differences in gp140-specific IgG2a levels were also statistically significant between the 
groups (p < 0.0001). The Vaccine+Sm mice group had a much lower IgG2a antibody response 
to gp140 (52.34 ± 4.67 AU) than the Vaccine mice (179.6 ± 13.21 AU).  Similarly, for gp140-
specific IgG2b antibody responses, the Vaccine mice had significantly higher levels of IgG2b 
in response to gp140 (261 ± 24.87 AU) than the Vaccine+Sm mice (150.2 ± 6.35 AU).  
3.3.2. Non-specific immunoglobulin responses 
Total levels of IgG1, IgG2a and IgG2b were elucidated for all four mouse groups from 
individual mouse sera.  These responses were not differentiated in vitro between those 
prompted by the vaccination nor those brought about by the parasitic infection.  All mouse 
groups demonstrated IgG1, IgG2a and IgG2b responses. 
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IgG1 responses were significantly greater in the groups that were infected with the parasite 
than the uninfected groups.  The Sm group elicited the highest IgG1 responses (224.8 ± 19.04 
µg/mL) which was significantly higher than all three other mouse groups.  The Vaccine+Sm 
group also demonstrated a significantly higher IgG1 response (143.8 ± 10.07 µg/mL) than the 
uninfected groups but significantly lower than the Sm group (p < 0.001).  The naïve mice 
elicited the lowest average IgG1 responses (58.29 ± 2.91 µg/mL) but this was not significantly 
lower than the levels produced by the Vaccine mouse group (61.54 ± 2.98 µg/mL).   
However, the total IgG2a responses were statistically highest in the sera of the Vaccine mice 
(361.5 ± 14.77 µg/mL).  The Vaccine+Sm mice (145.7 ± 18.04 AU) had significantly lower 
levels of IgG2a (p < 0.0001) but statistically higher than the mice in the two groups that were 
unvaccinated (naïve group p < 0.001; Sm group p < 0.0001).  The Sm mice had the lowest 
levels of IgG2a in the sera (29.58 ± 4.07 µg/mL), even significantly lower than the levels in 
the sera of the naïve mice (70.65 ± 4.66 µg/mL) (p < 0.0001).   
Conversely, the sera collected from the naïve mice appeared to have high IgG2b levels (17.03 
± 0.99 µg/mL) which was significantly higher than the Sm mice (p < 0.0001) and the 
Vaccine+Sm mice (p < 0.0001).  This was only slightly lower than the average IgG2b levels in 
Figure 3.11 - Non-specific antibody responses.  The total IgG1 (A), IgG2a (B) and IgG2b (C) levels were 
captured for each mouse sera which was collected by cardiac puncture 12 days after SAAVI MVA-gp140 boost. 
Bars represent the average comparable concentrations of Ig for each group (µg/mL). (**** p < 0.0001; *** p < 
0.001) 
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the sera of the Vaccine mice (17.10 ± 0.98 µg/mL).  The Sm mouse group had the lowest levels 
of IgG2b (9.48 ± 0.66 µg/mL), but not significantly lower than the levels in the sera of the 
Vaccine+Sm mice (10.03 ± 1 µg/mL).  
3.4. Histology 
3.4.1. Liver and spleen pathology 
Livers and spleens were harvested from the mice and, thereafter, weighed before the spleens 
were homogenised and the livers were stored in formaldehyde.  This indicates the probable 
degree of organ pathology (hepatomegaly and splenomegaly).  This would be further confirmed 
by the identification of granulomas in the liver and total splenocyte count. 
 
Figure 3.12 - The weights of organs harvested from mouse groups.  Spleens (A) and livers (B) were harvested 
from each mouse 12 days after SAAVI MVA-gp140 boost.  Bars represent the average weights for each group in 
grams. (**** p < 0.0001) 
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Figure 3.13 - The number of splenocytes per spleen harvested from mouse groups. Spleens were harvested 
from each mouse 12 days after SAAVI MVA-gp140 boost and pooled into each group. After the spleens were 
pooled, the concentration of splenocytes per ml were counted and extrapolated to total number of splenocytes. 
This could then be divided by the original number of spleens pooled per group. Data points represent each 
experiment repeat. 
Spleen weights (Figure 3.12 A) suggested that the parasitic burden in the infected groups 
caused splenomegaly in these mice.  The spleens of Vaccine+Sm group (0.544 ± 0.25 g) and 
those of the Sm group (0.481 ± 0.24 g) were statistically larger than the spleens of the 
uninfected groups; the Vaccine group (0.113 ± 0.035 g) and the naïve group (0.1 g) (p < 
0.0001).  Similarly, the average number of splenocytes collected per spleen for each group 
(Figure 3.13) was greater for infected mouse groups than those of the uninfected mouse groups, 
although this difference was not significant. 
Liver weights (Figure 3.12B) also indicated that infected mice, regardless of whether or not the 
mice received the vaccination, had some degree of hepatomegaly.  The livers of Vaccine+Sm 
group (2.239 ± 0.384 g) and the livers of the Sm group (2.306 ± 0.345 g) were significantly 
heavier than the livers of the naïve group (1.577 ± 0.174 g) and the Vaccine group (1.653 ± 
0.181 g).  This extra weight of infected mouse livers can be accounted for by the presence of 
granulomas, which was not observed in the livers of mice that were not exposed to S. mansoni 
cercariae (as shown in Figure 3.14). 
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Figure 3.14 - Photographs of liver samples.  H&E stained liver samples of A) Vaccine mice, B) Vaccine+Sm 
mice, C) Naïve mice, and D) Sm mice.  Granulomas were observed in the mice that were infected with the parasite, 
regardless of administration of the vaccine.  These granulomas were seen 68 days after infection with S. mansoni 
cercariae. The arrows (B and D) show granuloma formation. 
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4. Discussion
4.1 Overview
Parasitic worm infections and HIV are major health concerns in sub-Saharan Africa and the 
prevalence of these infections overlap substantially in many of these countries.  It is expected 
that successful future HIV vaccines will be targeted to people living in these regions. 
Therefore, it is likely that a large proportion of vaccine recipients, including children, will also 
be chronically infected with parasitic helminths.  It is likely that HIV vaccines will be 
administered to infants during childhood vaccination programmes to protect them from 
maternal HIV transmission through breastfeeding, and a booster vaccination will be required 
during adolescence to protect them against HIV via sexual transmission.  Currently, it is not 
known how an otherwise effective HIV vaccine would perform in the background of ongoing 
chronic helminthiasis given that helminthic infections have been shown to down-regulate Th1 
immune responses which are crucial for controlling viral infections (Reiner & Locksley, 1995; 
Hirahara & Nakayama, 2016).  This is particularly important for SSA and other developing 
countries where HIV and helminth infections are co-endemic and large portion of children are 
already infected or at an extremely high risk of contracting these parasitic worm infections 
(Davis et al., 2014; Shumbej et al., 2015). 
This study evaluated the immunogenicity of a candidate HIV vaccine regimen in the 
background of schistosomiasis to investigate whether helminth-induced immune responses 
have the potential to attenuate the boosting capacity of an HIV vaccine.  We used two candidate 
HIV vaccines to induce both cell-mediated and antibody-mediated immune responses in a 
mouse model of schistosomiasis to generate data that would inform on the potential impact of 
chronic helminth infection on the immunogenicity induced by HIV vaccines.   
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4.2 Reproducing a mouse model for schistosomiasis infection 
Schistosoma mansoni was chosen as a helminth model parasite due to its availability and 
established protocols in our collaborators facility, as well as the S. mansoni infection model 
being well-established in BALB/c mice (Actor et al., 1993; Da’Dara et al., 2006; du Plessis et 
al., 2013).  However, confirmation of the success of chronic S. mansoni infection was necessary 
before assuming cercariae-exposed mice were in fact chronically infected, and before 
conclusions could be drawn from the immunological data gathered.  In a mouse model, 
literature describes schistosomiasis pathology in mice as being chiefly associated with a 
granulomatous responses to parasite eggs that become lodged in the liver and intestinal tissue 
(Hams, Aviello & Fallon, 2013; Lundy & Lukacs, 2013).  Thus, validation of chronic 
S. mansoni infection in the mice challenged with the helminth cercariae could be achieved at
the experimental endpoint by observation of granulomatous inflammation in the liver and 
splenomegaly.   
The histology of the livers confirmed chronic infection at a physiological level by the presence 
of granulomas in the tissue (Figure 3.14).  Granulomas were observed only in the mice that 
were exposed to S. mansoni cercariae.  Similarly, the livers of helminth-infected mice were 
observed to be inflamed and of a greater average weight than the livers of unexposed mice 
(Figure 3.12 B).  Additionally, splenomegaly was confirmed by the weights of the spleens and 
number of splenocytes of the infected mice when compared to the unchallenged mice. As stated 
before, these physiological deviances are expected of chronic helminth infection and play a 
role in driving Th2 responses (Pearce et al., 2004; Hotez et al., 2008).  Thus, one can conclude 
that the mice challenged with the S. mansoni cercariae in the current study were indeed 
chronically infected, vis a vis the mice that went unchallenged were uninfected. 
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4.3 Helminth-induced down-regulation of Th1 responses 
To demonstrate Th1/Th2 biasing and thus down-regulation of Th1 responses due to chronic 
helminth infection, the ratio of secreted IFN-γ to IL-6 (the cytokines secreted in the highest 
levels) in response to ConA was calculated.  The results of the current study showed that the 
naïve mice had a greater Th1 biasing (Figure 3.6).  The Vaccine mice had a ratio of almost half 
the levels in the naïve mice, indicating a slight shift to Th2 due to the vaccine.  This may be 
due to the Th2 cytokines being secreted in response to the vaccine peptides as well as Th1 
cytokines.  The Sm mice had a ratio below 1.  This shows a remarkable Th2 immune biasing 
in response due to the helminth, a finding supported by previous studies conducted on the 
immune system of humans, as well as animals (Nutman, Kumaraswami & Ottesen, 1987; 
Grzych et al., 1991; Pearce et al., 1991, 2004, Araujo et al., 1994, 1996; Sartono et al., 1995; 
McKee & Pearce, 2004; Yin et al., 2012).  Thus, the baseline of mouse immunity to helminth 
being Th2 biased and mouse immunity to the vaccine being Th1 biased was established.  The 
Vaccine+Sm mice had a ratio of less than 2.  This is a vast decrease from the Vaccine mice, 
indicative of a further shift to Th2 biasing.  This finding is supported by an earlier study 
conducted on human subjects by Sabin and colleagues (1996), where subjects infected with 
S. mansoni were assessed for their ability to mount Th1 IFN-γ responses to a tetanus toxoid
(TT) vaccine as compared to an uninfected control group (Sabin et al., 1996).  The resulting 
data reported that the IFN-γ produced in response to TT was significantly diminished in the 
helminth-infected group (Sabin et al., 1996).  A more recent study by Yin et al. (2012) 
demonstrated that if the HIV DNA vaccination was administered before helminth infection, the 
vaccine is able to significantly reduce IL-13 expression and Th2 biasing induced by the chronic 
parasitic infection, and enhances expression of Th1 cytokine TNF-α.  Interestingly, these 
authors also reported that the vaccine had no significant influence on IL-4 or IFN-γ expression, 
when looking at the cytokines in the CD4+ cells (Yin et al., 2012).   
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To further support these data, total IgG1, IgG2a and IgG2b levels in the sera were quantified. 
It has long been established that the isotype of serum antibodies can be used to determine Th 
lymphocyte bias by virtue of the effects that certain cytokines have on immunoglobulin isotype 
selection in B cells (Finkelman et al., 1990; Mcsorley & Maizels, 2012).  As such, IL-4, a Th2 
cytokine, can induce B cells to produce IgG1 while simultaneously inhibiting IgG2a production 
(Snapper & Paul, 1987a,b; Deenick, Hasbold & Hodgkin, 2005).  Conversely, IFN-γ, a Th1 
cytokine, promotes IgG2a secretion and inhibit IgG1 secretion (Stevens et al., 1988; Deenick, 
Hasbold & Hodgkin, 2005).  Thus, the subtype of IgG secreted can indicate the cytokines being 
produced by T cells and the Th biasing.  We therefore also determined the total levels of the 
three subtypes in all the mouse groups and found that the Vaccine mice had the highest levels 
of IgG2a and IgG2b and the lowest levels of IgG1 indicating a very strong Th1 immunity, 
expected from a strong vaccine induced immunity.  Alternatively, the Sm mice had the highest 
levels of IgG1 and the lowest levels of IgG2a and IgG2b, again, indicative of a very strong 
chronic helminth-induced Th2 immunity.  The Vaccine+Sm mice had responses between these 
groups, showing that the vaccine does induce a Th1 response but that the helminth infection 
attenuates this response and shifts the immunity.  Vaccine+Sm mice had similar IgG2b levels 
to the Sm mice. 
These data indicate that there was a biasing towards a predominant Th2 immune response in 
mice infected with the helminth.  This can be reasoned to be caused by the immune responses 
caused by the chronic stage of infection (Maizels & McSorley, 2016). 
4.4 T cell responses 
The ability of the vaccine to induce Gag-, Pol- and Env-specific CD4+ and CD8+ T cell 
responses was elucidated by IFN-γ and IL-2 ELISPOT, CBA and ICS assays 2 weeks post 
boost.  The IFN-γ T cell responses as well as cytokine secretions to vaccine peptides were 
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shown to be attenuated in schistosome-infected mice.  Also noted was an observed shift from 
central to effector memory CD4+ T cell phenotype in these infected mice. 
4.4.1  IFN-γ- and IL-2-producing T cell responses 
As shown in Figure 3.1, vaccine-specific IFN-γ-producing T cell responses were significantly 
diminished in Vaccine+Sm mice.  In contrast, the accumulative IL-2-producing T cells (Figure 
3.2) were not significantly diminished in these Vaccine+Sm mice.  However, there was a 
significant decrease in IL-2-producing T cells in response to RT (CD4).  These diminished 
IFN-γ and IL-2 responses to viral antigens are in line with a previous study conducted by Actor 
and colleagues (1993) where they suggested this immune disability in helminth-infected mice 
might prevent the mice from clearing viral infections.  A study by Da’Dara et al. (2006) 
concurred with this finding with a S. mansoni-infection in a mouse model whereby a significant 
decrease in the frequencies of IFN-γ-producing CD8+ T cells was reported in vaccinated and 
infected mice compared to vaccinated and uninfected mice.  These authors went on to state that 
the chronic helminth infection nearly rendered the candidate vaccines unable to elicit Gag-
specific CD8+ T cell responses.  Apiwattanakul and colleagues (2014) reported that they too 
found that the effectiveness and immunogenicity of their pneumococcal vaccine was 
compromised in helminth-infected mice.  These authors, as with others, conclude that the 
attenuation of Th1 responses, such as IFN-γ production, together with increased production of 
anti-inflammatory and Th2 cytokines in helminth-infected vaccine recipients correlate with 
impaired vaccine efficacy  (Elias et al., 2001, 2005, 2008; Resende et al., 2007; Da’dara & 
Harn, 2010; Apiwattanakul et al., 2014). 
Nonetheless, the responses to SEA amongst mice that were vaccinated or not remained 
statistically unaltered.  This indicates that the vaccine does not inhibit the immunity mounted 
against the parasitic egg deposition in the tissues.  As responses to SEA are an indication of 
egg burden and degree of immunopathology in the host, this data suggests that the candidate 
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HIV vaccine used in this study does not worsen the schistosomiasis pathology, validating its 
safety for administration helminth-infected recipients (Abdelbagi & Eltayeb Omer, 2015). 
4.4.2  Th1/T2 cytokine secretion 
In this study, we also investigated the ex vivo secretion of key Th1 and Th2 cytokines in 
response to vaccine peptides between the Vaccine mouse group and the Vaccine+Sm mouse 
group.  Th2-type responses, commonly associated with chronic schistosomiasis, are typically 
characterized by increases in the levels of IL-4, IL-6 and IL- 13 (Yin et al., 2012).  Conversely, 
the vaccine would be expected to induce high expression of Th1 cytokines such as IFN-γ, IL-
2 and TNF-α which can inhibit the Th2 responses and vice versa.  We demonstrated that Th1 
cytokine secretion is generally decreased in response to vaccine peptides in the Vaccine+Sm 
mouse group.  The finding of a significant decrease of TNF-α secretion levels in Vaccine+Sm 
mice is supported by an earlier study by Yin et al. (2012) that illustrated a significant decrease 
in the intracellular levels of this Th1 cytokine in infected and vaccinated mice. 
Surprisingly, both Th2 cytokines quantified in this study showed significantly decreased 
secretion levels to vaccine peptides in Vaccine+Sm mice when compared to the Vaccine mouse 
group.  This suggests that the ability of the vaccine to stimulate IL-6 and IL-4 in response to 
the peptides was also attenuated by the presence of the helminth.  This finding is in 
contradiction with the study conducted by Yin and colleagues (2012) where by vaccination 
with their HIV vaccine candidate to mice infected with S. mansoni showed no significant 
differences in the levels of the Th2 cytokine that they assayed; IL-4.  This may be due to the 
fact that these authors assayed intracellular cytokine of only IL-4, and by ICS and FACS 
analysis, rather than a cytometric bead array, which measures the amount of cytokines excreted 
out into the medium, as used in our study.  Yin et al. (2012) measured total cytokine within T 
cells, whereas this study measured cytokine secreted specifically to vaccine peptides. 
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Therefore, this study demonstrates that helminth infection may suppress cytokine secretion to 
vaccine peptides, significantly for Th1 cytokine TNF-α, and Th2 cytokines IL-6 and IL-4.   
Da’dara and colleagues (2010) found that when stimulated with SEA splenocytes from infected 
mice had greater IL-4, IL-10 and IFN-γ secretion than naïve mice.  But when the same 
splenocytes were stimulated with ConA, infected mice only showed higher secretion of the 
Th2 cytokine (IL-4) and the regulatory cytokine (IL-10), but lower levels of IFN-γ secretion, 
when compared to the levels of naïve mice.  In this study, the cytokines secreted in response to 
SEA showed no significant differences amongst infected mouse groups.  However, IL-4 and 
IL-10 were slightly elevated in the Sm mouse group. 
4.4.3  Activated CD4+/CD8+ T cells 
We were unable to detect vaccine peptide-specific cytokine-positive CD4+ and CD8+ 
populations, most probably because the cytometry panel used was not optimal with regard to 
compensation for cytokines and their assigned PE fluorochrome.  As this is a tiny population 
of cells, incorrect compensation could have resulted in non-detection by a similar fluorochrome 
and thereby masking the cytokine fluorescence in the PE channel.  Therefore, this study went 
on to analyse the globally activated T cells (which were non-specific to HIV peptides) and their 
memory phenotypes of responding for comparisons across the various groups.  
The frequencies of globally-activated (CD3+CD4+CD44+) T cells in the spleens of 
Vaccine+Sm mice were significantly higher than Vaccine mice.  This was similar to trends 
seen for activated CD3+CD8+CD44+ T cells.  We delineated these cells further into effector 
or central memory T cell populations.  Although these two broad subsets are similar in 
expression of many costimulatory molecules, adhesion, and chemokine receptors, these 
populations have different functions (Schenkel & Masopust, 2014).  Central memory T cells 
(Tcm) cells express CD44+ and CD62L+ and they secrete high levels of IL-2.  After 
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stimulation and proliferation, they differentiate to effector cells able to produce effector 
cytokines (MacLeod et al., 2009; McKinstry, Strutt & Swain, 2010).  Effector T cells (Tem) 
cells also express CD44+ but not CD62L+ and can produce effector cytokines such as IFN-γ 
and IL-4 (Lefrancois, 2002).  
While there was a slight increase in percentage of central memory CD8+ T cells for the 
Vaccine+Sm group, the memory profiles of activated CD8+ T cells were comparable between 
infected and uninfected mice that were vaccinated, a finding supported by the results from the 
study by Shollenberger and colleagues (2013).  However, there was more variation in the 
memory phenotypes of activated CD4+ T cells whereby Vaccine+Sm mice had a greater 
proportion of Tem and a smaller population of Tcm memory T cells.  It could be proposed that 
the increased IFN-γ and IL-4 cytokine levels and the lower levels of IL-2 observed in these 
Vaccine+Sm mice may be due to this shift in memory profile from Tcm to Tem.  This shift in 
memory, and thus cytokine production is also supportive of the Th2 shift expected and 
observed in helminth-infected mice.  However, the memory phenotypes of the activated cells 
may be different from ELISPOT responding cells, as the activated CD3 cells detected by the 
ICS may not be secreting cytokine.  As such, the observable coincidences would need to be 
further investigated.   
The data is supported by previous studies on T cell memory profiles for helminth infection in 
mice (Shollenberger et al., 2013; Thawer et al., 2014).  In the study by Shollenberger and 
colleagues (2013), they stated that the biological relevance of this shift in activated CD4+ 
memory profile was unclear due to their lack of significant difference observed in Gag-specific 
IFN-γ ELISPOT results between infected and uninfected mice.  However, in this study, while 
we also saw no significant differences in T cell responses to Gag (CD4 and CD8) peptide, we 
did observe significant differences in the IFN-γ ELISPOT responses to the RT (CD4) and Env 
(CD4) peptide.  This may clear up the uncertainty behind the biological relevance.  
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4.5 Antibody responses 
Certain types of antibody responses to specific HIV antigens have been proposed to correlate 
with protection (Tomaras & Plotkin, 2017).  For example, the RV144 trail highlighted that 
IgG1 and IgG3 responses to the V1V2 regions of gp120 may be involved in protection against 
HIV-1 infection (Haynes et al., 2012; Tomaras & Plotkin, 2017).   
When stimulated by Th1 cytokines, B cells can produce IgG2a, whereas Th2 cytokines can 
induce secretion of Th2-type antibodies, such as IgG1.  IgG2b antibody is indicative of Treg T 
cells.  As such, the levels of these three isotypes of IgG, as well as complete IgG, specific to 
gp140 subunit of Env injected as part of the vaccine regimen, were analysed between the mouse 
groups.  These data show that while IgG levels as a whole to gp140 did not show a significant 
difference, the subclasses showed that the Vaccine+Sm mice had a significant increase in 
gp140-specific IgG1, and significantly lower levels of gp140-specific IgG2a and IgG2b when 
compared to the Vaccine mice.  Thus, the Vaccine+Sm mice have less Th1-type gp140-specific 
antibody levels in the sera than Vaccine mice.  However, the levels of Th2-type antibodies 
specific to gp140 were significantly higher in the Vaccine+Sm mice.  As these immune 
interactions are complex, these data can only suggest Th2 biasing caused by the helminth.  The 
observed increase in Th2-type gp140-specific IgG1 levels in schistosome-infected vaccinated 
mice may not necessarily be detrimental to the efficacy of the vaccine.  
4.6  Limitations 
Several studies have demonstrated the importance of HIV Env-specific neutralizing (Baba et 
al., 2000; Mascola et al., 2000; Burton et al., 2004; Barouch et al., 2013; Buchbinder et al., 
2014; Goepfert et al., 2014) and non-neutralizing antibodies (Aasa-Chapman et al., 2005; Holl 
et al., 2006) in protection against HIV.  Therefore, generation of high titres of both types of 
antibodies is considered as an important attribute of HIV vaccine-generated immune 
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protection. To generate an effective antibody response by vaccination, antigen-stimulated B 
cells must undergo class switch recombination and affinity maturation following contact with 
T cells in the germinal centre.  Repeated exposure to related immunogens by means of boosting 
inoculations has been thought to be a possible method to drive the B cells to produce broadly 
neutralizing antibodies (Dosenovic et al., 2015).  Neutralizing and non-neutralizing antibodies 
such as ADCC-mediating antibodies elicited by the vaccines against HIV-1 could also have 
been investigated in this mouse model by means of a standard TZM-bl assay (Pollara et al., 
2011 and Sarzotti-Kelsoe et al., 2014 respectively).  However, this was not possible because 
these assays have not been established in our laboratory and our resources were limited.  Other 
functional B-cell assays such as evaluation of avidity of gp140-specific antibodies by a sodium 
thiocyanate-displacement ELISA (Emmer et al., 2016) or by means of a B cell ELISPOT 
(Chege et al., 2017) were also not available.  As such, future studies could assess the vaccine-
specific B cell immunity to determine the helminth-associated Th2 biasing as suggested by the 
current study, attenuates the capacity of candidate HIV vaccines to elicit such responses. 
Vaccine-generated cellular responses that are mediated by IFN-γ, IL-2 and TNF-α are also 
thought to be important for a HIV vaccine (Morel & Turner, 2010; Belisle et al., 2011; Yin et 
al., 2012).  It is therefore important to characterise the phenotypes of T cells producing these 
cytokines.  The current study sought to determine the memory phenotypes and the proportions 
of cells that produced these cytokines by flow cytometry.  This was not successful, possibly 
because the flow cytometry panel was not optimally functional.  In future, an optimized 
cytokine panel for the detection of intracellular cytokines by ICS and FACS would prove useful 
to investigate whether helminthiasis changes the magnitude and frequencies of vaccine-specific 
memory T phenotypes.  More accurate indications of IFN-γ, TNF-α and IL-2 producing 
splenocytes of the mice could clarify more of the immunological responses of the combination 
of the vaccine and the helminth within the mouse model. 
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4.7 Conclusion 
In conclusion, the findings of this study suggest that contracting a chronic helminth infection 
in between primary and boost vaccinations may have some disastrous effects on the vaccine-
generated Th1 responses such as IFN-γ T cell responses.  The secretion of Th1-type cytokines, 
and indeed Th2 cytokines, may also be inhibited by helminth infection.  The memory 
phenotype of activated CD4+ T cells is shifted by the helminth to a greater effector memory 
profile, and a greater central memory profile of activated CD8+ T cells.  Importantly, and even 
surprisingly, the Env-specific humoral responses may be altered by helminths, leading to a bias 
to Th2 responses which could potentially dampen the efficacy of the vaccine-induced 
immunity.  This study justifies further studies, possibly using a nonhuman primate model, to 
obtain an in-depth understanding of these immune responses.  
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Appendix 1 
10x Lepple Buffer 
 5.6 g CaCl2
 12.28 g MgSO4.7H2O
 0.43 g K2SO4
 4.2 g NaHCO3
 0.48 mL FeCl3.6H2O solution (2.5 g dissolve in 50 mL H20)
The chemicals were dissolved in 1 L distilled water, except the NaHCO3, and allowed to stand 
for 1 hour. The NaHCO3 was added and the solution was made up to 10 L with distilled water. 
To make a working stock of 1x Lepple buffer, 1 part 10x Lepple buffer was added to 9 parts 
distilled water. 
